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ABSTRACT
Tumor necrosis tactor-« (TNF·a) is a cytokine with inflammatory and
requlatory properties produced by monocytes and activated r-ceas. Levels of TNF-
a secretion in~ by peripheral blood mononuclear cells (PBMC) st imulated with
bacterial lipopolysaccharide (LPS) or phorbol tz -mvrtstate ta -ecetete (PMA) plus
concanavalin A (ConA) have been reported to vary among individuals and to be
associated with HLA-DR alleles, namely HLA-DR2 with low levels of TNF-n
secretion and HLA-DR3 and DR4 with high levels.
In this study we have measured levels of TNF-a secreted by ~PS-stimulat ed
PBMC from 72 healthy young males. There was a large degree of varlanon in the
level of secreted TNF-IX and this interindividual variation was relatively stable in
four individuals tested 2 to 4 times. The study panel was also typed for HLA-DR,
-A, -B and -C antigens. A weak association was shown between HLA-DR3 and low
levels of TNF-a secretion (p = 0.014, uncorrected). No association was shown
between levels of TNF-a secretion and HLA-DR2, -DR4 or HLA·B antigens.
We further explored the possibility that differences in levels of TNF-a
sec retion might be due to (1) individual differences in the kinetics of TNF-a
secretion and/or (2) differences in the relative number of TNF·" secreting cells
when different stimulants were used. The kinetics of 20J1g1ml LPS-induced and
1nglml LPS-induced TNF-a secretion by PBMC were very similar but the total
amounts secreted were hIgher with 20 I!glml LPS. The kinetics of TNF-a secretion
were quite different when PBMC were stimulated by LPS or ConA plus PMA. LPS-
induced TNF- cz peaked a a to 6 hours while ConAJPMA-induced TNF-cz secretion
dicl not reach an obvious peak in our experiments but was low at 3 hours and
continued to rise at 53 hours. Five individuals were classified as higl to low
secretors us ing the 3-hour. 20 I!wml lPS, stimulation protocol. This classification
changed dramali cally when the ConNPMA, 53-hour protocol was used and mree
ind ividuals classified high became low or vice versa. This is an important
observation and must be considered when investigating assoctauons between
levels of TN F-u secretion and HLA anllgens.
To investigate if differences in secretion might be due to individual
diffe rences in the number of TNF-u secret ing cells, a two-colo r immune-
lIuore scence assay was developed to monitor cell phenotype and cytoplasmic
TNF -a by f l'JW cytomelry. There was no consistent relationship between the
proportion of CD 14 monocytes in the samples staining positive for cytoplasmic
TNF-a and the levels of secreted TNF-a by LPS-stimulated PBMC from two
indiv iduals tested, but this may have been due to technical diffic.... lties. However.
differential counts of the male study panel PBMC samples by flow cytornetry for the
subsets CD14 monocytes. CD4 T-cells, CDa t -eensand CD45RO r -eeus showed
no correlation between the relative numbe rs of cells in each subset and secreted
TNF-u leve ls.
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Chap ler I
Introduction
1.0 Historical Background
During the latte r part of the last century physicians noticed thai if p atients
with tumors cont racted erysipe las, a Streptoc occus ovrogeo es infection of the skin,
the ir tumou rs shra nk during the cou rse of the lntecncn . Dr. Wm. B. Coley (Coley ,
1893) discovered that he could prepare crude baclerial extra cts and use them as
a treatment for sometypesof tumors. This preparation becameknown as Coley's
Toxins and was the only approved systemic trea tment for cancer until the advent
of chemotherapy and radiation in 1934. T he treatment was eventually abandoned
because of ils toxicity to the patients.
InterestinColey'sToxins wasrevivedduring the 1930'swhen researchers
were interested in isolating and purifying the bacterial factor that induced tumor
necrosis and separating it from the toxic material in the crude bacterial ext racts.
Shears and colleagues (Shears, §l..a!. 1936; Hartwell,~. 1943) purified a
' bacteria!polysaccharide" which was very effective ininducing tumor necrosis. This
material however, was very toxic and its use as an anti-tumor agent wa s not
carried any further.
Bythe 1980's workon the necrosis causedby "bacterial polysacchardes" ,
now called lipopolysaccharide (LPS), started again because il was now
hypothesized that the mediator of LPS·induced necrosis was not LPS lteelt but
some endogenous material produced in response to LPS (O'Malley~ 1962).
O'Malley demonst rated that serum derive d from endotoxin-treated mice could
induce haemorrhagic necrosis of tumors of untreated mice. A similar observation
was made by Carswell !tl..m. (1975) with serum from mice treated with Bacillus
Calmelle-Guerin (BCG). The factor responsible was heat labile ar.d was termed
tumo r necrosis factor (TNF). Meanwhile, in the 1970's, Rouzer and Cerami (1980),
working with rabbits, demonstra ted that animals with Trypanosoma brucei
infec tions developed hypertriglyceridemia and ·wasting· or cachexia. The elevated
trig lycerides were shown to result from a deficiency in lipoprotein lipase. In a series
of experiments with endotoxln -resfstent (C3H/HeJ) and endotoxin-sens itive mice
(C3H/HeN) , Kawakami and Cerami (1981) demonstrated that a serum factor , which
they called cecnectln , was responsible for cachexia.
By the mid-1980's both tumo r necrosis factor-a; and cachectm had been
seq uenced and the chromosoma l location found (Beutler!H...m.. 1985, Caput~.
1986, Nedwin~. 1985). These studies showed that TNF-Il and cachectin were
in fact the same molecule.
1.1 TNF-a and TNF.p
Two bIological molecules, TNF-Il and TNF·~, now use the name tumor
necrosis factor . TNF-P, originally called lymphotoxin, was thought to be of diff erent
cell ular origin than TNF-a.. TNF-P was considered to be mainly a lymph ocyte
product andTNF-ll a monocytelma::rophageproduct (seesection 1.5 for review).
It is now clear thatTNF-a is produced by a wider variety01cell types than is TNF·
p. Some cells can make both. which one depending upon the signal the ceO
receives.
TNF· ll also has a much broader spectrum of activity than TNF-p. For
example,vascular smoothmusclecell expression of HLA-DR (Stemme~. t 990)
and macrophage production of macrophage calony-silmulating factor (Oster .el..J!.
1987) are influenced by TNF-u but not TNF· p, In some cases where there are
shared effects, one may have a greater effect Ihan the other.
More lnfarmallcn on profound differences betweenthe Iwa molecules Is
slaning 10 emerge. Mos! of these differences ere at the production level, such as
mode ofproduction, transcriptionrates and different regulatory sequences (Ruddle
1992). ThF·a and TNF·p show a limited amino acid sequencehomology of about
30% (Pemica~. 1984), but have an almost identical structure (see section 1.2).
Both genes are single copy genes of roughly the sene size closely linJced 00
chromosome 6.
1.2 TNF-" structure
TNF-ll is secretedas anunglycosylated, 157-amlno acid polypeptide with
a molecular weight of 17 kOa (Jones m...m. 1989). The biologically active form of
the secreted molecule isa 52·kDa trimer in which monomers are held together by
single, intercha in, disu lfide bonds (Aggarwal~. 1985). The tertiary structure of
each subunit is unusual because it has a typical jelly ro ll- ~ structure, a structure
common to vira l capsid proteins. The most striking structural similarities are with
thecapsid prot eins of elcosahecral plant viruses. particularly the Satellite Tobacco
Necrosis Virus (STNV) , with 70% struct ural homoloqy (Flers 1991). TNF-a is the
first non -viral protein found to have this structure.
The complete carboxyl termina l end of the molecule is essential for
bioactivi ty (Beuller and Cerami, 1988). Genetic manipulation of the prima ry
structure has shown that the amino term inal can lose up to eight residues without
loss of bioactiv ity but the carboxyl terminal must rema in lntect.
TNF-o:also ex istsin a 26-kDa integral transmembrane form (Krigler et at
1988). In addition to the 157 residues of the monomer s of the secreted form, the
membrane-bound for m lias an additional 76 residues which traverse the
membrane. Th e 17-kDa secreted protein is derived from the 26-kDa form by
proteolytic cleavage f rom Ihe 76 residue lntram embrane portion.
The 2&kDa membrane bound Iorm has been shown to be biologicaliy
active (Perez !ilU.!. 1990). Mu tant ce lls that are unable to secrete TNF-o: but
express the m embrane- bound form, have been shown to kill tumor cells and virus-
infected cells directly by cell to cell contact. The same mutant cell type not
expressing TNF -a on the mem brane did not have this cytotoxic activity.
1.3 Actions on Cells
TNF-« isa m ultifunctional cytokine affecting many different cell type s and
elic iting a plethora of different activities in difforent cells. This diversity of activity
can be ascribed 10 muhiple sigoal transduction pathways and activat ion of a large
number ofgene s. The following sect ions will describe some of d'lese activities and
the role of TNF-u in the immune response.
1.3.1 TNF Recep tors
TNF exerts Its activityupona ceU byfirst binding 10specificTNFreceptors
(TNF-R). Two dist inct receptors have been identif ied, TNF-R1 (TNF-R~ ) and TNF-
R2 (TNF-Ra ) (Brackhau5 ~.•1990). with different molecular weights.
immunoreactivities and glycosylation patterns. There is only 28% homology
between the extracellular domains of these mole cules and no homolog y belween
intracellular dcmalns, suggesting that the receptors have different signalling
pathways (Lewis §U!.. 1991). HohmaM gUI. (1990) however, presented evidence
tha t both receptors activate a common transcription tactor, NF-KB. Both TNF- a and
TNF ·p can bind to either receptor .
Both receptors are found on most cell lines (Kull eu1. 1985;Bag1i0i1i m
m. 1985; Aggarwa l ~. 1985) and on nearly all cells of somatic tissues, except
erythrocytes (Beutler & Cerami, 1988). Using fl ow cyt ometry to quantitate the
number of recep tors per cell, Gehr ~.A!. (1992) have shown that there are no
significant differences among peripheral blood mononuclear subsets in numbers
of either receptor . This observation also holds true afte r phytohaemagglutinin
(PHA) stimulation, which activates CD3-positive lymphocytes.
The signa ls from each receptor may not be redundant; each may be
responsible for different ectivrtes. Usir.g recep tor-specltc antibodies, it was
demonstrated that TNF-Rl signals cytotoxicity and induces several genes while
TNF·R2 signals proliferation in primary thymocytes andcytotoxic 't-eens (Tartaglia
~. 1991). Gehr ~. (1992) however, somewhat contrary to these findings,
showed that both receptors can elicit a proliferative cell response and that the
response is greatest if both receptors are activated. In this study the proliferative
response was dim inished by blocking either of Ih 13 receptors with antibodies.
One very important feature of TNF receptors is their ability to be secreted.
Secreted forms have a lower molecular weight bu t retain the ability to bind TNF.
The secreted forms were first ldenfffledas TNF-bi nding protein (TNF-BP) in urine
(Engelmann~. 1990; Seckinger ~...§!. 1988) and serum of cancer patients
(Gatanega at at 1990). AggarwalgtID . (1988) has shown that, inm, membrane
TNF-R's on monocytes and macrophages are rap idly downregulated by phorbol
esters (phorbol 12-myrlstate 13-acetale (PMA)), IL- l and TNF-(t . Gatangea!ll.A!.
(1991) went on to show thaI part of the downreg ulation that occurred when cells
were stimulated with PMA and LPS was due to secretion or shedding of the
receptor into the supernatant.
1.3.2 Tu mor Cells
Hi storically , TNF- « was first ide ntified an d named for its anti-t umor
activity. Th is activity was ob served Inm with the fib roblast-like L·92 9 cell line and
in~ in the necr o sis of Meth A sarcom as implan ted in mice (O 'Malley .eL§1.
1962). Be cause of lbese initial findings there was grea t enthu siasm for the
pot ential use of TNF -a as an entt-tumcrth erapy.
Further researc h in the therapeutic uses of TNF -a as an anti-tumor
treatment has show n that the early enthusia sm may have b een prem ature. Not all
tumor cells respond to TNF -a ,and those that do. show a wide variety of responses
(Ortafdo.!2L§!. 1986; Tsulimotc §!..ill. 1985). Besrstance to TNF·« appears n otto
be due to a lack of receptor s on the cell but 10 the absence of a blcchemcat s ignal
aft er TNF-a binds 10 the receptor (Suga rman~. 1985). Tumors that are
resistant 10 TNF-a ill~ can sometimes be suscep l ible to necros is if!vivo if the
tumor is vascular ized. In this ca se it ap pears th at TNF~ a acts indirectly by
destroying the vasc ular en dothelium in the tumor, th us cutt ing off blo od flow to the
tumor (Pa lladina llil. 1987).
TN F-a can also aCI as a gr owth factor for s ome malig nanc ies. Chro nic B-
ce ll malignancies, su ch as hairy ce ll leukaem ia, have been s hown 10 proliferat e and
to produce TNF-« when treated w ith TNF-a (Cord ingley a t al. 19BBa).
1_3.3 Sep tic Shock
It has long been observed that patients suffering from acute bacterial
infections can very quickly go Into septic shock. Symptoms include fever, chills,
nausea and in severe cases, may rapidly result in death. Pat ients sulfering from
chronic disease, such as cancer or tcberculosls. suffer cachexia or wasting,
characterized by a loss of muscle and adipose ttssue. In the last century when
Coley was treating patients with Coley's toxins, it was noted that many of the
patients suffe red symptoms similar to those of bacterial infections. and in some
pa tients, severe septic shock (Spooner&ID. 1992).
Research into the role of TNF-" in septic shock has taken several
app roaches. One was to measure plasma TNF-a levels in critically ill septic
pat ients, such as those with meningococcal (Waage and Espevik, 1987) and other
diseases (Debets~. 1989). Not all the septic palients had detectable levels of
TN F-tt, but those that did had a much higher mortality rate than TNF-tt negative
patients. The lack of delectable circulating TNF-« does not preclude its elfects.
The detection limit of the assays used in these studies may not have been low
enoughand TNF-a has a short circulating half·l ife. Also, ceu-assoclatec forms of
TNF -a:may act via paracrine mechanisms (Perez fH...§!. 1990). Another approach
was to infuse animal s with rTNF-a. Both rats (Tracey and Seuller 1986) and dogs
(Tracey~. 1987) given quantities similar 10those produced endogenously in
response to LPS died within minutes 10 hours.
Cancer patients with advanced tumors treated with TNF-a: suffer
hypotension , leukopenia, and renal impairment, symptoms associated with septic
shock (Selby~. 1987). In fact, the maximum tolerable doses are much lower
Ihan those required for maximum cytoxicity to Ihe tumor cells.
1.4 Effects on the Immune System
It is now generally accepted that TNF·a secreted at low levels In localized
infections acts as an immune modulato r. In this context it probably has a protective
role in helping to eliminate the infectious agent.
TNF-o: is primarily an m.cmmetorycvtoklne, acting as an early response
cytcklne in cellular activation and propagation of the inflammatory response. 115
major role is to initiate and resolve a local inflammatory response. One of the first
events in a local inflammatory response is the trapping of neutrophils II ::' e area.
TNF-a stimulates the vascular endothelia l cells 10release a neutrophil chemotactic
Iactor (Moser et at 1988) and may be chemotactic ilself in allracling leukocytes
(Ming .!ll...m. 1987). Neulrophils also have increased phagocytic properties and
increased superoxtde production in Ihe presence of TNF-a (Klebanoff gUJ. 1986).
At the same time TNF·a increases the adhesiveness of neutroph ils to endothel ial
cells by upregulating the expression of adhesion molecules such as intercellular
adhesion molecule (ICAM) and endothelial-leukocyte adhesion molecule (ELAM)
(Griffiths~. 1989). TNF-o: also upregulates Class I MHC molecules (Pohlman
!ll..m. 1986) and attracts macrophages to the site of inflammation. TNF·a can Ihen
stimulate these macrophages to produce more TNF-a and stimulate endothelial
cells and macrophages to produce IL-1. Both TNF-a and IL-1 can trigger lever.
TNF-a may also function as a co-stimulator for T-lymphocytes (Zucali at at 1987),
may modulate a-lymphocyte differentiation (Kashiwa~. 1987) and may exert
anti-viral activity similar to that of IFN-y (Ohase 2t.i.!. 1986; Wong and Goedde!
1986).
The observed effects of TNF-a on the immune response are not
necessarily a direct result of TNF-a activity, bul may be the result of a second or
third mediator produced In response to TNF-a activity. 11 Is now commonplace to
discuss these phenomena as the "cytokine network." where one cytokine
stimulates the production of a second and so on. TNF-a , for example. can
stimulate the production of interl<aukin-1 (IL-1) by macrophages. Both of these
cytokines can stimulate the production of inlerleukin-6 (IL-6). IL-6 can then
stimulate lymphocytes. activate haematopoietic cells. and induce acute phase
proteins (reviewed in Van Snick 1990).
1.5 TNF-« Secretion
When TNF-a and TNF- ~ were first identified. it was thought that TNF-ll
was a monocyte/macrophage product (Carswell~. 1975) and TN F- ~ was a
lymphocyte, particularly T-Iymphocyte, product. It Is now known that TNF-a can be
produced by many different cell types of immune origin, including lymphocytes, NK
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cells, and Kuplfer cells, as well as cells of nonimmune origin, such as endothelial
cells (Aggarwal & Vilek 1992) and smooth H"Jscle (Warner & Libby 1989).
1.5.1 Monocytes/Macrophages
Macrophagesare lhe primary sourceof TNF-a (Beutler & Cera mi 1988 ).
This isnot surprisingconsideringIhe role TNF-Cl pla}'3in inflammation and the fact
that macrophages are among the first cells to arrive at a locali zed st e of infection.
Allmacrophages Ihat have been tested thus far, including macrophages derived
from peripheral blood monocytes, Kupffer cells and peritoneal macrophages,
produce TNF-a.
Both the secreted soluble 17 kDa form and the cen-surtacebound 26-kDa
transmembrane form are produced by monocytes (Kriegler~. 1988). It is
suggested that surtace-bound TNF-a may playa role, such as killing of target
cells, by ceu-to-cencontact. Most TNF-l1 research however, has been on the
secreted tonn.
ill~ \3xperiments have shown that a variety of agents can induce
macrophages to produceTNF-u, but lipopolysaccharide (LPS) from gram negative
bacteria is the most potent stimulus (Beutfer & Cerami 1987). Not all types of LPS
are equally effective. Bacteria expressing the rough LPS phenotype are better
inducers of TNF-l1 than bacteria with smooth LPS, possible because rough LPS
is shed more readily (Kelly.eu!. 1991). Also, long chain polysaccharides attached
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to the Upid A moiety reduce the ability to induce TNF-" . Very small amounts of
LPS. as low as 12 pgIm~ can slimulate monocytes 10 secrete TNF·" and the
amount of TNF-« secreted is dependent on the LPg concentralion (Molvig~.
1988). Coocentral ions of a tew picograms up to micrograms per millil itre are
routinely used (Cutun m...l!. 1987; Aderka~. 1989; Jacob~. 1990). The use
of microgram quantities of LPS to induce TNF·« secretion by cells in culture has
been criticised because such large quantities may be greater than levels achieved
ill vivo . Lynn .§Ul. (1993) point out however, mat LPg concentratioos up 10 Ilg/ml
can occur with fecal soiling of the peritoneum and in abscess cavities.
For monocyte acuvatton. exposure to LPg need only be a few minutes.
LPS binds to monocytes very quickly (Gallay~. 1993). Within 5 minutes near
maximum binding 10 the cell has occurred. and the cells continue to secrete TNF-"
afler extensive washing to remove the lPg. A rapid burst of secreted TNF-o: is
seen within 20 minutes of LPS exposure (Hofsli~. 1988).
TNF-a is not secreted constitutively (Hofsliga[. 1988; Beul :er~. 1986;
Lonnemann~. 1989), but there are conflicting reports as to whether non-
stimulated. circuhli ng monocytes contain non-translated TNF-« mANA. Some
researchers have shown lhat resling monocytes contain a small pool of non-
translated TNF-o: mANA and thallhis mANA may be translated in the first lew
minutes of cellu lar stimulation to account for the Initial burst of secreted protein
{Holsli~. 19BB). This initial burst can be inhibited by cycloheximide. a protein
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synthesis inhibitor , but not by actinomycin, an RNA synthesis inhibitor. Beutler gt
l!!. (1986) also report finding low TNF-a mRNA levels in fresh monocytes but
question whether it was induced by Ihe lsclanon procedures of the experiment.
Both groups report not finding any TNF-a from Iysates of restirlg cells, suggesting
that TNF-a mANA in resting cells is not translated. After LPS stimulation, there is
a rapid increase in TNF-a mRNA demonstrated by nuclear run-on transcription
assays. In contrast to these studies, Sariban §U!l. (1988) reported that TNF-a
mANA was absent in resting monocyles but was quickly induced after stimulation.
LPS stimulates monocyles to produce TNF·a by first binding 10 receptors
on the cell surface. There are a number of reports of the different mechanisms by
which LPS can bind to monocytes, and more recently the finding of more than one
type of receptor (reviewed by W~ight, 1991) (See table 1 for a list of receptors).
CD14, a surface protein found on monocytes. macrophages and
polymorphonuclear leukocytes, is the classical receptor for LPS. The existence of
CD14 as a monocyte antigen has been known since the mid-1960's (Goyert at at
1986) but was only recently shown 10 be a receptor for LPS (Wright .etA!. 1990).
LPS does not bind CD14 directly, but lirsl complexes with a serum protein called
LPS-binding protein (LBP). LBP was first discovered in Ihe mid-1980's and shown
to have a role in Lpg- induced sepsis and acute phase reaction (Tobias~. 1986;
Tobias ~. 19a8~ but its mechanism of action was unknown. II is now known Ihal
monocytes are activated when CD14 binds LPS-Lap complexes.
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LBP appears not to be the only serum protein that can complex with LPS
to bind CD 14.A second serum factor, called septln. has been shown to opsonize
LPS-bearing particles and then bind to CD14 (Wright~. 1992). II is distinct from
LBP because its activity is not blocked by anti·LBP antibodies. The molecule (or
molecules) also appears to have proteolytic activity because its activity Is blocked
by protease inhibitors.
New evider:ce indicates that neither CD14 nor serum factors are essential
fo r monocyte activation by LPS to produce TNF·" (Lynn ~. 1993). THP-1 cells,
a human monocytic cell line, can still produce TNF-a In response to LPS
stimulation when grown in serum-free media . At low LPS concentrations in serum
free conditions, the amount of TNF~a secreted is much lower than when serum is
present at tho same LPS concentrations. In this situation, the increase in TNF-"
by adding serum to the culture can be blocked by anti-CD14 antibodies. At high
LPg conce ntrettons in serum-free media however, there Is increased TNF' 1l
secretion and the levels of TNF'1l secreted is affected very little by the addition of
serum. Secretion cannot be blocked by antl·CD14 antibodies at high LPS. Thus,
anti·CD 14 affects TNF'1l secretion only jf serum or LBP is present. These results
clearly point to the existence of other LPS receptors that are not LBP-dependent.
There is a growing pool of evidence that other LPS receptors do exist.
The C0 11/CD18 family of adhesion molecules on leukocytes have been shown to
bind LPS (Wright & Jong 1986) There is some doubt, however as to whether these
'4
receptors are involved tn LP5-:nedialed signal transduction becauseCD1B-deficient
cens slill respond to LPg (Wright at at 199Ob). 11"ta most promisl1g cand idate as
a second LPg receptor is a 70-S0 kOa protein lound to bind LPS to mouse
scieoccvtes (Lei gLa!.1988) and more recently to human monocytes, Iymfi'locytes
and polymorphoouc lear leukocytes (Halling ~. 1992). Another membrane
associated protein. MW 30-40 kOs, also binds LPS and is a possible receptor
candidate. A 95 kOa ·scavenger" receptor may also playa role in LPS activa tion
of monocytes (Morrison~. 1993). [Table 2)
These non-C0 14 LPS pathways may be important at sites of infection
where LPS concentrations are very high (Lynn §U!. 1993). C01 4·LBP dependent
pathways may be more important for circulating monocytes where the LPS
concentration would be very low.
Monocyles express receptors (FeR) for the Fc portion of immunoglobulin
molecules. To date there are three FcR's known to exist on monocytes . FeRI
(CD64), a high allinity receptor. and FcRII (C0 32). a low affinity recepto r, are found
on all mcnccytes (Oebets eLi!. 1985). More recently, FcRIII (C0 16) has been
reported on a subset 01monocytes (Passlick m...m. 1989) .
Crosslinking FcRI with immune complexes or IgG bound 10 plastic wells
can stimulate monccytes 10secrete TNF-a (Debals.iLW. 1988; S:zaboM . 1990).
FcRI/ appear to bind the immune complex es or Immobilized 19G only alter
treatment ~·. il h proleases (Oebels~. 1990). Alter treatmen t of these recept ors
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they can be crosslin ked and induce TNF- (l. secretion. TNF-o: secretion stimula ted
by FcR cross linking may be importa nt when monocytes are presented with
antibody -coated antigens, such as viruses and pa rasites. and in antibody- mediated
cellular cytotox icity.
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Table 1: list of Reported Possible LPS Receptors
Receptor Cell Type lPS ·Serum References
Factors Complex·
CD14 Monocyte Ves Wright et a (199Oa)
Goyertet at. (19861
CD111CD18 Leukocytes No WrYj't.et do (199Q)1
Wright & Jong
11980)
70 to 80-k Da Murine aplenccvtes 1 lei et al. 1198BI
protein Human leukocyte s No Hallingetal.119921
30 to 40 ·kDa Murine lymphocyt es Reviewed in
protein Morrison 0' st.(19931
95-kOA Macrophages Reviewed in
scavenger Wrightet sJ. (19911
receptor
• Indicates whether LPS i irst binds to a serum fact or to form a complex and the
complex then binds to the recept or
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A variety of other agents have been used experimentally 10 induce the
secretion of TNF-a . The most commonly used is a phorbol ester, 4p-phorbo l 12-
myristate t a-ecetate (PMA) or O-tetradecano ylphorboI 13-acetale (TPA). PMA is
a nonspec ific cell activator of a wide variety of genes in a wide variety 01cell lypes
(Castagna U. 1982). Cells of the monoblastoid line, U937, are not responsive
to LPg but will produce TNF- a within 2-4 hours after exposure 10 PMA (Hass !;11
ID. 1991). Freshly isolated human mooocytes will also secrete TNF-a after PMA
exposure (Nedwin QUI . 1985;Saribon lliJ. 1988). Using nuclear run-on assays,
TNF-a mANA has been detected within 20 minutes of PMA exposure. Secreted
protein is detectable after 3 hours and increases progressively.
1.5_1A Monocyte Sub sets
Subsets of monocytes may differ in TNF-a production. In 1989lhere was
a report of the finding of a new subset of monocyte s (Passl ick at at 1989). These
cells had lower levels of C014 expressed on the surface. higher MHC Class II
molecule expression and, unlike "regular" monocytes. expressed C016 (FcAlt l) on
their surfac e. These cells were also not adherent to plastic and were not
phagocytic when tested with antibody-coated erythrocytes. They were smaller and
less gran ular than other monocytes.
Wang at af. (1992) also reported the existence of two sets 01monocytas,
based on size alone. One group was roughly twice the size of the other but stilt
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displayed monocyte characteristics. such as non-specific esterase staining. When
stimulated with l PS, the smaller cells secreted lower levels 01 TNF-Ct than the
larger cells. Ziegler-Heitbrock et at (1992) reconfirmed the existence of smaller,
CD14/C0 1S·posiUve.monocytes and showed that. when stimulated with LPS, they
produced 10-fold lower levels of TNF-« than regular CD14-positive monocytes.
This new CD14/CD16·posilive subset. representing about 9 % of
peripheral blood monocytes, has been further characterized by immunofluoresce nt
assays for surface antigens and slot blot RNA hybridizationa for transcript levels
(Ziegler-Heitbrock at at. 1993). Because of their lower CD14 expression they are
generally denoted as CD14'/CD16 monocytes while , regular monocytes are
denoted CD14' " mcnocytes. CD14' /CD16 monocytes have four-fold lower levels
of CD14 expression but approxImately eight fold higher levels of MHC Class II
expression. There is an increase in VLA-4 expression, a surface molecule involved
in leukocyte-endothelial cell interactions and in expression of ICAM-1 on some
CD14' /CD 18 cells but not on CD14' " cells.
CD14'/CD 16 monocytes show many of the same characteristics as
alveolar macrophages . In fact. Passltck et at (1989) reported that these cells could
be found in large numbers in alveolar space. The authors suggested that they may
represent CD14' " monocytes at a further differentiation stage because when
CD14' " monocytes are lell in culture for 5 days they show many of the
characteristics of CD 14'/CD16 monocytes. Scheibenbogen & Andreesen (1991)
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reported that up to 70 % of fresh monocyles that had been left in culture for 14
days were expressing C016 . It had been reported several years pr ior to the
discovery of this novel monocyte subset that the ability of monocytes to produce
TNF· « decreases when the cells are left to differentiate into macrophages inY11!2
(Burchett.e1J!!. 1988).
1.5.2 Lymphocytes
While monocytes/macrophages appear 10 be the primary source 01TNF·
e, both T- and B-Iymphocyles can produce TNF· cx , at least in ~, in varying
amounts depending on the stimulant used. Lymphocytes, in culture. are
unresponsive to LPS. They are responsive to phorbol esters and cross-linking of
various surface molecules with immobilized immunoglobulin.
1.5.2A T Cells
Both human T-cell lines and fresh peripheral blood T-lymphocytes produce
TNF~a when stimulated with phorbol esters and calcium ionophores (Kinkhabwata
m...ID. 1990; Culur i ~. 1987), These studies have shown that the effects 01
phorbol esters and calcium ionophores are additive. Both TNF· a mANA and
secreted protein can be detected earlier than when cells are stimulated with either
phorbol ester or calcium ionophore alone. When cells are stimulated with PMA
alone TNF-a mANA can be detected within one hour after stimulation (Sung !!U!.
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1988).
There are a number of molecules on the surface of 't-eens that are
important in ceu-to-cef interactions and antigen presentation. CD3 for example, is
associated with the T-call receptor and is involved in T-cell activation during
antigenpresentation by anligen-presenlingcells.Becausethesesurface molecules
are involved in cell activalion, and cell activation often involves one or several
cytoklnes. there has been a Ilurry of research in TNF-o: production by cell
activation through these molecules. There have been a number of studies
demonstraunq that cross-linking CD3 on 'r-ceus with immobilized anti-CD3
antibodiescan stimulate TNF-a production (von FJiednergL§!. 1992; Chong.m...e.J.
1992; Sung §La!. 1988; Turner~. 1987). Soluble anli·CC.3antibody IHIS no
affect on TNF· « production. Again, co-atlmulatlonwith PMA can increase TNF-«
to higher levels than stimulating with PMA or anti-C03 alone. Co-stimulating with
anti-C028 antibodies alsoaugmentsTNF-« production overC03 stimulationalone.
C02 is amolecule found on most thymocytesandmature peripheral blood
'l-cells . It is an adhesion molecule involved in interactions with endothelial cells,
connective tissue and most blood cells. Santis et af. (1992) demonstrated that T-
cells could 1I~ stimulatedthrough C02 to produceTNF-a.. Two different monoclonal
anti-C02 antibodies, each recognizing different eprtopes. were required for
sustainedTNF-« production. Co-stimulationwith PMA or calcium ionophore greatly
augmented the amount of TNF·« produced.
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COG9 is a surface molecule not found on resting lymphocytes. It is the
earliest inducib le surface antigen during lymphocyte activation. Fresh peripheral
blood 'r-cene can be induced to express COG9with PMA. Stimulating the cells with
immobilized anti-COG9 can induce the cells to produce small amounts of TNF-a
within 24 hours (Santis el at 1992b). Co-stimulating with PMA stimulates the cells
to produce more TNF-« than stimulation with anti-C OG9or PMA alone.
Lymph okine-activated kilier T-celis (LAK-T), T-cells that can kill target cells
in a non-MHC restricted manner, can also produce TNF-a (Chong U . 1992).
LAK-T cells were stimulated by co-culture with anti-C03 'and K562, a FeR
expressing tumo r cell line. This tumor cell line would immobilize the anti-C03
through Fe-FeR interactions, Immobiliz inganti-CD3 by absorbing onto plaslic plates
gave the same results. However, co-culture with non-FeR expressing tumor cells
could also augmen t TNF-a: production. Antibodies to adhesion molecules, such as
LFA-1, LFA-2, CD44 and CD45 could also augment TNF-a production when the
cells were cultured with anti-CD3. The interactions with these adhesion molecules
on the non-FeR expressing tumor cells could account for their enhancement of
TNF-a production.
Staphylococcal enterotoxin A (SEA) can induce both monocytes and T-
cells to produce TNF-a if the cells are cultured together (Fisher at at 1990), SEA
alone does not stimulate either T-cells or monocytes to produce TNF-a. Addition
of other cytoklnes. such as IL-2 or IL-4 to monocyte/SEA cultures does not induce
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TNF-a , therefore an unknown mediato r or direct cell-to-cell interaction Is required
in this situation . On ly CD4 ' "r-ceuscan induce monocytes to produce TNF-u in Ihe
SEA stimulati on sys tem (Fisher~. 1990).
Not all T-cell subsets produce TNF-a to the same extent. Bolh CD4 and
COB T-cells can produce TNF -u but CQ4 T-celtsproduce lev els 3-fold higher than
COB cells (Cutu!i ~I a!. 19B7). C045RO' t -eens(memory cells ) when stimulated
with anti-CD3 and PMA produce 10-fo ld higher levels than CD45RO· T-cells (von
Fliedner gUJ. 1992) ,
Physiologic ally, TNF -a from T-cells may act more in a paracr ine manner
at localized sites of infection and/or tissue injury. Adhes ion mo lecules for example ,
such as lFA's, help hold ce lls together for TcR-CD3 engagement during antigen
prese ntation. Engagement of lhe adhesion molecules may enhance TNF-u
sec retion. COG9' "l- cells are localized at sites of tissue injur y. TNF-o: secreted
through the COB9act ivation pathway may contribut e to tissue injury, such as in the
synovial membranes 01rheum atoid arthritis.
1.5.28 B Cells
B-cells are now recognized as a source of TNF- u depending on the
stimulation pathway . PMA slimulates tonsillar Becellsto secrete very low levels of
TNF ·u , in compar ison to T-celis and monocytes . but if co-st imulated with
~~ Cowan Strain 1 (SAC) there is an increase in both secreted
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TNF-« and mRNA (Sung m..Jl!. 1988) . Tonsillar B-cells also secrete TN F-a when
co-stimulated with SAC and IL-2 (R ieckmann ~. 1991). Pre- S cells lines, such
as Josh-7 and Nalm-6, do not produce TNF-« when stimula ted with SAC and
PMA, suggesting a developme ntal regulatory mechanism.
From a physiologica l perspect ive, TNF-« secretion from B-cells activaled
through surface immunoglob ulin binding 10 antigen may be more significant.
Goldl ield !ll...A!. (1992) has shown that cross-linking surface immunoglobulin
molecules on B·cells with an ti·human 19 (lgG, 19M, IgAl can stimulate TNF-«
sec retion. This TNF· a could be an important mediator in Ig secretion because
TNF -a can enhance 19secretio n.
1.5.3 Perip heral Blo od Mononuclear Cells
Some researchers have used PBMC stimulated !!lm to Siudy TNF-«
sec retion. This system avoids some uorecessary manipulation of cel ls because
they are sUbfecled to only one separalion process and mimics physiological
condi tions as closely as possible. In mixed cell populations however , only total
secreted TNF· a can be m easured. It is difficult 10 dete rmine the relative
contributions ofeach cell type to the total TNF-a secreted. Because we know that
different cell types are activated bydi fferent agents, the choice of stimulating ag8111
becomes important in interp reting the data.
For example, 8endtzen §1.gj (1988) stimulated the ir cultures of PBMC
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w ith LPS, therefore the TNF-o;secreted was most likely by monocytes. Malave ~
~ (1969) f''1dJacob~ (1990) stimulated cells with a combination of PMA and
Concanavalin A (COfl Aj for up to 3 days. Con A is a plant derived lectin that is
known to stimulate r-ceus to proliferate. The secreted TNF-a in this situation is
probably derived from several sources, monocytes and 't-eens . The relative
contributions of each may change over time as the T-eall numbers increase.
1.5.4 Methods for Measuring TNF-a
In the study of TNF-a production, a number of different experimental
systems have been used. In addition to using PBMC, or subsets of PBMC, different
cell lines have been used. The two most commonly used are THP -1, a monocyte
line and U937, a pre-monocyte line. THP ·1 cells can be stimulated by LPg to
produce TNF-a but Ue37 cells must be pretreated with PMA to induce further
differentiali on.
BothTNF·a mRNA and secreted protein have been measured in dillerent
systems to monitor TNF-a;production. Secreted protein has been measured by two
main methods, with a bioassay and with an Elisa. The bioassay is a cellular
cytotoxicity based assay that uses cell lines sens itive to the cytotoxic activity 0:
TNF-a t such as the mouse fibroblast cell line L·929. The bioassay measures only
b iologically active TNF-a; while the ELISA can measure total protein, The main
disadvantage of the bioassay is ils lack of specificity. Itwill measure other cyotoxic
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sub stances that ma y be present with TNF- a in the sample, such as TNF-ll .
1.6 Variation in Secreted TNF-. Levels
Ther e are a numbe r of reports demonstrating tha i (here are stable
inte rindividual diffe rences in secret ed T NF·« from fresh periph eral blood
mon onucle ar cells. Molvig §.U! . (1988) first reported met, when fresh monocyt es
from healthy males were st imulated in~ with LPS, there were lilfere nces
among indi viduals in the amo unt of TNF-« secreted and the se diffe rences were
sta b le over time. Jacob ~. (1990) also made a similar observat ion tor m ales
us ing a combination of Con A and P MA as stimulant. Secreted TNF-a. from males
an d pcst-meoc pausal females when tested several times was hig/lty reprodu cible.
Pre -menopausal te meles however, showed largeinterindividu al differeno 3b U1the
diff erences were not stable over time .
Most reports describing TNF 'a: secretco by freshly purified peripheral
blo od monocytes st imulated with LP S repo rt peak secretion levels bet ween 3 and
6 hou rs (Lonnemann~. 1989; Beutler & Cerami, 1988). The amount of T NF· I'I:
in the culture supernatant slowfydi m inishes aller about sbo urs . There areno clear
kin etic stud iesofTN F·a sec retionw hen renotcretb rood mon ocyles ar e stimulaled
wi th PMA . Sariban~ (1988) reported a peak secretion level at 15 hours and
Nedw in~ (1985) reporte d a pea k secretion level at 24 hours. However , these
ex p eriments ware not carried beyond 15 an d 24 hou rs. With a mon ocyte-like cel
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line, U937, a plateau of secreted TNF·(I secretion was reached at 48 ·72l1ours
when stimulaled with PMA (Hass~. 1991).
The kinetics ofTNF·(l secretion by lymphocytes is less clearly understood
than secretion bymonocytes. In most experiments secreted TN F-cr: was measured
at only one or two time periods (G oldfield §UJ. 1992; Santis~. 1992). In
experiments where cells were stimulated fo r 2 - 3 days secreted TNF-a was
measured only once or twice. TN F·(I mANA however, was measured more
frequently in these experiments so there are better kinetic studies of mRNA
synthesis tharl secreted prote in. B-cells, when stimulated with SAC for example
have peak TNF-o.m ANA levels at 32 - 48 hours (Sung~. 1988). Even though
Ihere are no true kinetic studies of secreted TNF-« by lymphocytes, we do know
lhal bolh T- andB-Iymphocytes when stimulatedcan sustain TNF·(I secretion for
at least up to 48 hours afte r stimulation (von Fliedner U1. 1992; Sung .m....m.
198 8).
Some researchers have chosen to use whole blood or mixed peripheral
blood mononuclear cell cu lture because the results may be more relevant to
physiological conditions. Whole blood stimu lalions with LPg had peak TNF-a
secretion at 4 - 8 hours (A llan ~. 1992; Strieter gLgl . 1990). Purified peripheral
blood mononuclear cells stimu lated with LPS in the same experiments had peak
secreted TNF·C( bioactivity at 24 hours.
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1.7 TNF-« and HLA
In humans, the TNF-" gene maps to the short arm of chromosome 6
(Nedwin m...m. 1985). It is found within the MHC cluster of genes. about 230 kb
centrome ric to HLA-B and appr.Jximalely 870 kb lelomeric 10 HLA-DR genes
(Carro ll gLg!. 1981) (Figure 1).
Th& mapping of the TNF-a 990e within the MHC Class III reg ion
prompted speculation about the role of TNF- o: In the eUology 01 MHC-Iinked
diseases. Molvig~. (198B) first suggested a possible association betw een both
low TNF -« and low lL·1 respon ses and HLA·D R2 when monocytes from heallhv
males were stimulated with low lPS for 20 hours. It is not stated whether the
subjects were typed 10f' HLA-B. Bendtzen.euI. (1988). using a panel of 39
subjects ofboth sexes ranging in age from25 to 52. demonstrated that PBMCfrom
HLA-OR2 ind ividuals secreted less TN F-" .inYi1r2 when stimulated w ith 1 nglml
and 100 nglml LPS for 20 hours thannon-HLA-OR2individuals. Subjects were also
typed forHLA-A, -B,.c, and -op but no associationwas found. Incontrast10the
Molvig~ (1988) data, there were no observedcorrelations with HLA-DRand the
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Fig ure 1: Molecular mapof th e MHC region showing the dist ances be tween
TNF-a and HLA-DR and HLA-B. (Adapted fr om Trow sdale et al. 1991 )
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IL·1 response. Preincubation of the cells with IFNoy for 16 hours augmented the
LP$-induced TNF-o: secretion in both HLA·DR2+ and HLA-DR2" individuals and
caused the difference in secreted TNF-a levels between the two groups 10
disappear .
Jacob illl. (1990) reported a similar observation for a p-met of healthy
males whose mononuclear cells were stimulated in~ with a combination of Con
A (10 ~glm l ) and PMA (2 ng/ml) for approximately 60hours. In addition 10 the low
TNF·o:secret ion and HLA-DA2 associalio n, they reported that HLA·DA 3 and ·DR4
individuals were high TNF·o:secretors. DR2I3 and DR2J4hele rozygoles were also
high secretors. There were no HLA·A, -S, or -C associations observed. Although
the data reporled were for ConA!PMA stimulations because it gave the highest
levels of secreted TNF-o:I the authors report thai other reagents were used 10
induce TNF· o:, such as 10 ~glml LPS for -60 hours, and the interind ividual
differences between high and low secretc rs were the same for all memods. (Table
2).
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Table 2 : Report ed HlA-DR Associations with TNF-a Secretion levels
Assoc iati ons
Aut hor Cell Type Stimulant Time
HLA-DR2 HLA-DR3 HLA-DR4
Molvig et al. (198B I Monocvte LPS 20 hrs low NT NT
12 .5 pg/ml
to 250 ng/m l
Bentzen er al. (19881 PBMC LPS 20 hrs low no NT
1 ng/ml
100 ng/ml
Jacob et al. (199 0) PBMC ConA /PMA - 60 hrs low high high
Mo lv ig et et, 119901 Mo nocyte LPS G hrs no no NT
13 pg/ml & 20 hrs
to 250 ng/m l
Sachs et al. (1990 ) PBMC PHA 7 2 hrs
Picot et st. 119931 Monocyte LPS 20 hrs low high high
250 pg/m l
low "" low levels of secre ted TNF-a
high "" high levels of secre ted TN F-a
NT = not tested or not reported lnpaper
no = no association foun d
1.8 TNF-a and Disease
There are a number of reasons why there is interest in the role TNF-o:
may play in disease. The initial area of research was in the role TNF-« may play
in Infectious diseases, suchas in inflammalion, and in the elimination of infectious
agents. A second area of research was prompted after the mapping of the TNF-o:
gene to the human and murineMHCregions. Thi s initiated speculation that TNF-lX
may play a role in HLA- linked autoimmun e diseases, or serve as a better marker
for autoimmune disease. The following two sectlons will address the role of TNF-lX
in infect ious diseases and its possible role in autoimmune disease.
1.8.1 TNF-Ct and Infectious Diseases
There are many infectious dise ase causing agents that stimulate the
production of TNF-a, including both Gr am negat ive and positive bacteria, fungi ,
parasite s and viruses. The result may be ben ef icial wit h the elimination of the
agent, or delete rious, depending on the quantit y produced and time period ove r
which production is sustained. Septic shock is the most common disease state
fromthe overproduction of TNF~« Inresponse to an infec tiousagent, usually Gram
negativ e bacteria. Malaria is also a potent inducer of TNF·" and infected
individuals with high serumTNF- l1levels areat risk ofcer ebral ma laria (Kwiatowski
WI. 19 90).
TNF-a plays an lmponant rol e in th e protection from a number of
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infectiousagents. Mice forexample,when passively immunized againstTNF-" with
anti-TNF-" antibodies, readilysuccumb to Mycobacterium bovis. (Beutler & Grau,
1993). A similar protective effect of TNF-a is seen during infections with~
monocvtogenes Legionella pneumophila, and Plasmod'um berghei.
1.8.2 TNF-tt and Autoimmune Disease
There are a number of autoimmune diseases that are associated with
different MHC alleles. Ankylosing spondylitis , for example, has a very strong
association with Hl A-B27 and SLE has an association with HLA-BB and OR3
(TIwari & Terasaki 1985). The role of the MHC Class I and II genes in the disease
state is still no t completely understood, They may be the predisposing genes bu t
equally maybe marker s for other closely linked genes. TNF-Q; is a candidate for
one of those marker or predisposing genes because il is found within the MHC
cluster and is a potent modulator of the immune system. Muller~ (1987) in
fact, hypothesised thai a dysregulated TN F-a gene may be involved in
autoimmunity.
Jacob & McDevitt (1988) reported a possible link between TNF-" and
disease in the (NZB x NZW)F1 mouse, a model for SLE. The NZW mouse Is
phenotypically normal but the NZB has mild glomerulonephritis. The F1 hybrids,
however, suffer severe gJomeruJonephr jlis and 95% die within the first year .
Peritoneal exudate cells from the NZW animals secrete lower levels of TN F-a tha n
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cells f rom NZB mice. and the F1 hybrids have an intermediatelevel which is closer
to levels secreted by NZW. Treating the (NZB x NZW)F 1 withTNF-tt early resulted
in prolonged life. At 11 monms 90% were still alive while 80% oltha non-treated
animals were dead. The authors suggested that the NZW parent contributed a
gene that produced low levels 01TNF-« .
Malave m....e.!. (1989)stimulated PBMe' s from healthy individuals as well
as SLE patients with active and inactive disease . When stimulated with CanA plus
PMA there was maximum TNF-IX secretion between 48 and 72 hours lor all
groups. Con A alone caused very lillie TNF-n sec retion. With Con AlPMA
stimulations. patients with active SLE secreted less TNF'a than controls. The re
was no significant difference between patients with inactive SLE and controls. In
addition, spontaneous TNF-tt secretion in unsti mulated cultures was higher in the
SLE group.
SLE nephritis has a stroogassociation with HLA-DR2 (Tiwari & Terasaki.
1985). The combined data of the (NZB xNZW )Fl studiesand the work of Jacob
U . (1990) showing low TNF-(t production a ssociated with HLA·DR2 suggests
TNl=·a may pl ay a role in SLE nephrit is. In teet . the Jacob~. (1990) report also
pointed out tha t HLA-OR3 and -DR4 individuals have highTN F-a production and
SLE patients wit h these haplotypesare not predisposed tonephritis. Jacob (199 2)
has suggested that, with SLE, TNF-a may have a primary involvement in the
autoimmune process rather than acting m ainly as the effector arm of the
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inflammatoryprocess In organ destruction .
Rheumatoid arthritis (RA) has a strOtlg association with HLA.{)R4 bu t no
associationwith TNF -a production levels has been demonstrated(Maury& Teppo
1989). TNF·a probab ly playsan important role in tissuedestr uction in RA becaus e
TNF-a has lhe ab ility to stimulate collagenase and cause bone and ca rti lage
resorption (Beutle r & Cerami, 1987). Mau ry & Tempo (1989) did show that RA
patients ha veelevatedseru miNF-a levels andBuchan m....ID. (1988) reported that
TNF·(X cou ld be detected in the synovial fluidof RA patient s. TNF'a does not
appearto playa role in the predisposition of a person to develop RA. In this case
it appears tobe more of the effectorarm of the inflammatoryprocessthat leads
to bone and cartilage destruction .
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1.9 Alms and Objectives
This project began in the context of (i) inconclusive data regarding HLA
associations with leve l of TNF·cr: production and (ii) a system in place in this lab
for studying TNF·a induction and quantltaticn which had been optimized for
anot her study . Indivi duals in this laboratory had been using 20 j.Lg/ml of l PS to
stimulate TH p·1 cells and a cytotoxicity assay to measure secreted TNF. In this
system TNF producti on peakedbetween :3and 6 hours after stimulation. The init ial
objectives of this pro ject we re :
(a) to verify, using 20 J.LQ/ml LPS for 3 hours as inducer and human
PBMC as the source of TNF-a, that the level of TNF·a production by
PBMC of d ifferent individuals varied and that the levels were stable
over time,
(b) to determine whether the reported associations between HLA and
TNF-a leve ls could be verified using the experimental conditions
described in (a),
and because thecyto toxicity assay was very sensitive to, but not specific for TN F·
e ,
(c) to develop an ELISA to quantify TNF-a in (a) and (b) .
Bec ause we were unable 10 verify the report Ihat HLA-DR2
associated w ith low T NF'a expression and, in ourexperimental conditlons, found
that DR3 w as associated with low express ion. we hypothesized that fthigh
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expression" and "low expression" might be affected by the conditions under which
TNF-a was induced. Thus , one objective was then to :
(d) to carry out kinetic studies to investigate
(I) the pattern 01TNF-a secretion over lime in " high" and " low"
individuals
(Ii) the differences in TNF· a secretion induced by different
inducers and different concentrations 01 the same agents. For
example , high lPS, low lPS arid Can AfPMA .
Peripheral blood mononuclea r cells are a mixed population of cells In
which the sizes of subsets vary from individual to individua l and possibly also in the
same individual over l ime. An ideal experiment might compare, in a group of
indivi duals, the TNF-a produc ing capacity of a known number of cells of each
subset. Such an experiment would be arduous and also subject to technical
difficulties, such as the possible TNF-a induction in some cells by the reagents,
such as antibodies, used to purify them. Thus, the final objectives were:
(e) to develop a two-color flow cytometry assay to monitor the cell
types and the number of each cell type in a sarnph of PBMC that are
producing TNF- a at a given time when different inducing agents are
used to induce TNF-a production
(I) 10 determine the relative number of cells in each PBMC subset of
differenllndivlduals 10determine if the number 01cells 01a particular
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subset correlated with levels of TNF-ll secretion.
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Chapter 2
TNF· a Secretion and HLA Assoc iations in Healthy Males
This chapter describes the development of an ELISA for TNF-a,
exper iments to determine interindividual va riation of TNF-a secret ion by a group
of healthy males and experimen ts to investigate associat ions between levels of
TN F-a secretion and HLA.
2.1 Methods and Materials
2.1.1 Reagents
2.1.1A Cell Culture Malerials
Cell culture medium was RPMI 1640 (Gibco/B RL. Burlington) wlth the
following additives:
10 % fetal ca lf serum (FeS ) (GibcoIBRL)
2 mM L ·glutamine (Gibco/BRL)
50 1I Penicillin G (GibcolBRL)
50 l1g1ml Streptomycin sulfate (Gibcol8RL)
5 J.1M 2-merca ptoet hano l (2-ME) (Sigma , St. Louis)
2.1.18 Buff ers
(1) Phosphate Buffered SaUne (PBS) pH 7.2, 1QX
80 9 sodium chloride (Fisher Scientific)
2 9 potassi um chloride
14.4 9 sodium phosp hate, dibas ic
2.4 9 potassiu m phosphate. monobasic
Add disti lled water up to 1000 ml
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distilled
To make tx PBS , 10X stock was diluted by adding 1mlto 9 ml
water
(2) Coating Buffer fo r ELISA. pH 9.2
0.159 9 sodium carbonate (Fisher Scientific, Montreal )
0.293 g sodium bIcarbonate (Fisher Scientific, Montreal
100 mt distilled water
(3) Blocking Bulfer (1 % eS A·PBS)
1 g Bovine Serum Albumin (BSA) (Sigma. St. Louis )
100 ml PBS
(4) Citrate Buffer for ELISA Substrate . pH - 5.1
a. 0.1 M citric acid: 0.96 g citric acid (Fisher Scientific) + 100 ml
distilfed water
b. 0.2 M sodium phospahte dibasic : 1.41 9 sodium phosphate
dibaslc (Fisher S"ien tific) + 100 ml distilled water
The buffe r was then prepared by mixing 4.9 ml 01 (a), 5.1 ml of (b)
and 10 ml distilled water.
(5) Substrate for ELISA
8 mg o-phanylenediamlne (GPD) (leN Blcmedicafs. Mississauga)
20 mt citrate bu ffer
8 III 30 %-hydrogen perox ide (Fisher Scientific, Montreal) • added
immediately befo re use
(6) Washing Buffer (PBS-O.S % Tween)
500 IJI Tween-20 (Fisher Scientific, Monlreal)
1000 mt PBS
2.1.1C Anti bodies
(1) Purified Mouse Monoclo nal anli -TNF·a (lgG,l (Endogen, Boston)
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(2) Purified Rabbit Polyclonal anti·TNF-cx (19G) (Endogen, Boston)
(3) Purified Goat anti-Rabbit - Horseradish Peroxidase Conjugate (GAR-
HRPO) (Southern Biotechnology, Alabama)
(4) Purified Goat anti-Mouse - Horseradish Peroxidase Conjugate (GAM-
HRPO) (Southern Biotechnology, Alabama)
(5) Purified Normal Rabbit 19G(Southem Biotechnology, Alabama)
(6) Purified Normal Mouse IgG (Southern Biotechnology, Alabama)
2.1.10 Other Materials
Flat bottomed96-well polystyrene plates, o-phenylenec1iamine (OPO)
and normal goat serum were purchased from ICN Blomed'cats,
Mississauga.Bovine serum albumin (BSA), lipopolysaccharide (LPS) (£,
QQ!i Serotype026 -66), Tween-20 and2-mercaptoelhanol were purchased
from Sigma, SI. Louis. Lvmphoprep' " , a sterile solution of 9.6 %lsodium
Metrizcata and 5.6 % polysaccharide, was purchased from GibcolBRL,
Burlington. Recombinant TNF-a (rTNF'a) waspurchased from Boehringer
Mannheim, Montreal.
2.1.2 TNF-a ELISA
The ELISA used to measure secreted TNF-a was a modification of the
indirect sandwich ELISA by McLaughlin gU1 (1990). All volumes -'<\ J0ed to the
wells were 50 1-11 and all washes were with PBS-Tween unless otherwise noted.
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The inner 60 wells of flat bottomed 96-well polystyren e plates were
coated with mou se monoclonal anti-TNF·/Xat 2 ~g1ml by adding 50 ~ l of anlibody
diluted in coating buffer at pH 9.2. Plates were covered and incubat ed overnight
aI 4°C.
Afler coating, coating buffer was removed by flicking the plate and bloll ing
on paper towel. Any remaining protein-bin ding sites were blocked with 200 Il Vwell
of blocking buffer for 1 hour at room temperature.
A rTN F-a standard curve was generated by preparing serial dilutions from
7 nt}'m l to 0.054 nglm! rTNF-(t in culture medium. The first dilution was prepared
by trans ferring 1.4 1-1 1of a 10 I-lglml stock rTNF-a solution inlo 2 ml of diluenl to
give a concentration of 7 nglml. Doubling dllutlons were prepar ed in 500 ~I 01
diluent.
After blocking, blocking buffer was removed and the plates were washed
3 lime s. Each standard dilution , sample , and negative control, consisting of only
culture medium, were added in duplicate wells. The plates were covered and
incubated overn ight at 4°C
After washing the plat e 3 times , the secondary antibody was added to
each well and incubated for 2.5 hour s at room temperature. The secondary
antibody was a polyc'onal rabb it anti·T NF-a diluted 1:300 in 1% goat serum in
PBS.
The conjugate was a horseradish peroxidase conjugated goat anti-rabbit
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(GAR-HRPO ) diluted in 10/0 goat serum-PBS. The dill.l ion factor had been
previously determined and had to be dete rmined for each new fat. Genera lly the
dilution factor was from 1:3000 to 1;40(iO. Afler washing the plate 3 limes, GAR-
HRPO was added 10 each well and incubated for 90 minutes at room temperature.
The color was developed with a-phenylened iamine (OPD) and hydrogen
peroxide in citrate buffer as substrate. 100 ~I of the substrate was added to each
well including the first column of wells to act as a blank. The plate was incubated
at room temperature in the dark for 30 minutes. The reaction was stopped by
adding 50 ~I 012.5 M H2S0 4 to each well. The optical densities (0 0) were read
at 490 om on a Bic-Bad Microplate Reader (Model 3550) interfaced with a
computer with Microplate Manager software (Blo-Had, Mississauga, ON) for data
analysis.
Standard curves were generated with OD's plotted against log standard
rTNF-a concentrations. TNF-a concentrati ons in the samples were determined by
reading directly from the standard curve. The limits of detection of the ELISA were
54 pglml to 6 000 pglml TNF-« but the useful range for reliable measuremen ts
were 54 pglmllo 3500 pg/ml.
2.1.3 Development of TNF-CtELISA
The following sections describe the steps Ihat were taken to optimize
sensitivity of Ihe ELISA for the part icular antibodie s and different lot numbers of
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antibodies that were used.
2.1.3A Determination of Conjugate Dilution· Goal an ll·rabbil·HAPO
Thirty of the inner 60 wells of a flat bottom S6-well polysty rene plale were
coated w ith 50 !J.Vwell of normal rabbit IgG and the remaining 30 wells were coated
with norma l mouse IgG at 5 IJ.glml in coatin g buffer (pH 9.2) overnigh t at 4°C.
The following dilutions of GAA -HAPO were prepa red in 1% goat serum-
PBS: 1:500, 1:1000, 1:1500, 1:2000 , 1:2500 , 1:3000, 1:3500, 1:4000, and 1:4500 .
Each dilution as well as a negative control, which was diluent alone, were tested
in triplicate against both the rabbit IgG and mouse IgG.
Aller coating , the plate was washed twice with PBS, blocked for 1 hour
with 200 IJ.Vwellof block ing buffer, followed by washing 3-times with PBS-Tween.
Aliquots of the GAR-HRPO dilutions were added to the prate at 50 IJo l/wel l. The
plate was incubated at room temperature for 90 minutes.
Colour was developed with 100 IJo Vwell of substrate buffe r for 30 minutes
in the dark. The reaction was stopped with the addition of 50 III 2.5 M H2S04 and
OD's read at 490 nm.
The conju~ ate was routinely tested in this manner and the working
dilution adjusted accordingly (see Results ). In addition, each new 101 was also
tested befo re use.
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2.1.38 Determination of Concentration of Coating Antlbodv
Of the Inner 60 wells of a 96~well polystyrene plate, 36 were coated with
monoclonal mouse anfi-TNF·o: at 5 concentrations from 1 ~g/m l to 5 ~glml in
coating buffer. Six wells were coated with each of the different concentrations and
six wells were not coated bul received only buffer. TI.e plate was incubated over
night at 4cC.
The following day the plate was washed with PBS, blocked for 1 hour with
200 \! lIweli of blocking buffer followed by washing 3 times with PBS-Tween. For
each of the five sets of six wells coated with the different antibody concentrations,
three received 50 ubwelt of GAM-HRPO diluted accordingly and the other three
wells received GAR-HRPO for 90 minutes at room temperature. Three of the
uncoated wells received GAM-HRPO and three received GAR-HRPO. GAR·HAPO
was included to determine if it bound non-specifically to the coating antibody
because in the TNF-cx ELISA, GAR·HRFO would be the conjugate used. The plate
was then washed 5 limes wilh PBS·Tween and colour developed with OPO as
described previously.
2.1.3C Determination of Secondary Antibody Concentrations
Mclaughlin at ar. (1990) reported using polyclonal rabbit anti-TNF-o: at
1:300 dilution, Iherefore several dilut ions in this range was chosen to test. The
dilutions were 1:100, 1:200, 1:300 and 1:400 in 1% goat serum-PBS. In addition,
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because the sensitivity of the ELISA was not known at this point several rTNF-a
concentrations were used in testing the secondary antibody. Three concentrations.
10 ng/ml, 5 ngfml, 1 ngfml were arbitrarily chosen and 700 ~ I of each were
prepared in culture media. The range of Mclaughlin's ELISA was 0.08 ng/ml to 6
nglml. but the useful range was from O.OS nglml to about 2-3 nglml.
The inner 60 wells of a Ilat bottomed plate were coated with monoclonal
anti-TNF-a as previously described. After blocking, 50 1-'1 aliquots of the three
rTNF- " concentrations were each put into 15 wells and the remaining 15 of the
60 wells received 50 j.L 101culture medium. The plate was covered and incubated
overnight at 4°C.
Each of the polyclonal rabbit anti-TNFo« dilutions were tested in duplicate
against each of the rTNFo« concentrations and against the wells coated with
culture medium. In addition, normal rabbitlgG diluted 1:100 and 1:400 and dilution
buffer alone were tested against each of the rTNFoa concentrations. After adding
50 j.Lllwell of these materials the plate was incubated at room temperature for 2.5
hours.
The plate was washed three times and GAR-HRPO. diluted as in section
2.1.3A, was added to each well for 90 minutes at room temperature. After washing
an additional five times color was developed with OPD substrate.
2.1.30 Determination of Range of Sensltivily
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To determine the useful range of tha ELISA, rTNF-a concentratlons
ranging from 10 ng/ml lo 0.013 ngfml were tested in triplicate using the antibody
concemrattons prev iously determined. When the upper and lower sensitivity limits
were determined, the standard curve was tested :3 times to determine if it was
reproducible before assaying samples.
2.1.3E Coefficient of Variat ion (CV)
The CV was determined by testing a sample with a known concentration
of TNF-a each time the ELISA was run. This sample had been prepared bydil uting
rTNF-(l to a concentration of 2500 pglml in culture medium and st"ring at ·700C
ill 100 ~ I allquots. The concentration of the sample read from the standard curve
was used to calculate the CV. As a control. this sample could test both reliability
of the standard curve and the variability in the ELISA from day to day.
2.1.4 Collection of Samples
Healthy male volunteers between the ages of 20 and 30 years were
chosen. Most were medical students that were also part of another study. Care
was laken to exclude individuals with know current infections and taking
medication. Blood samples were collected by venipuncture between 8:30 am and
12:00 noon. A maximum of 5 donors were bled on any given day. A tolal of 6 x 10-
ml Vacutainer (Becton-Dickinson, Buthertord. NJ) tubes with ACD (acid-citrate-
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dextrose) as an anticoagulant were collected from each subiect. One tube was
used for TNF-a experiments and the remaining blood was used for Hl A-typing,
differentia l blood cell counts and other cytokine studies.
As part of a similar study, blood was collected from a panel of pre-
menopausal females, 20 - 30 years of age. once a week for a 4 to 8 week period.
At each sampling lime TNF-a:production was induced using the same protocol as
used for the males. This laUer work was done by two summer students. Paula
Rowe and Nancy Sampson.
2.1.5 Preparation of Cells
Peripheral blood mononuclear cells (PBMC) were isolated from lresh
blood using Lymphoprep' " . 10 ml of blood was diluted with 10 ml of sterile PBS
then layered onto 4 ml of LymphoprepTM in each of two 15 ml centrifuge lubes at
room temperature. The tubes were centrifuged at 800 x g for 30 minutes. The
PBMC form a distinctive layer which was removed with a Pasteur pipet. The cells
were washed twice with culture medium, counted and resuspended al 1 x 10e/ml
in culture media.
2.1.6 Induction of TNF~a Secretion
TNF-a secretion was induced with 20 IJglml LPS for three hours.
Previous work in the lab by Claire Simpson had shown thatlhe monocytic cell line,
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THP-l, secreted the highest amounts of TNF- ll when stimulated with 20 J,lwml
LPg for 3 and 5 hours. LPS concentrations from 1J,lgfml to 20 J,lg/ml had been
tested in that study and secreted TNF· ll had been measured by a bioassay which
measured biologically acnve TNF-« .
Freshly isolated PBMC were plated out at 200 J,lVwell (200 000 cells/well)
in 3 wells for each subject in a sterile 96·well round bottomed plate. The cells were
incubated at 37"C in a humidified COa-incubator overnight.
T~e following day the plates were centrifuged at 800 x 9 for 10 minutes.
Supernatants were removed with a sterile pipet and discarded. Fresh media with
20 J,lgfm l LPS was added to two of the wells and fresh medium without LPS was
added to the third well to serve as a negative control and to determine if the cells
were secreting TNF-« spontaneously. The cells were then incubated at 37"C for
three hours. After incubation the plates were centrifuged at 800 x g for 10 minutes,
the supernatants were removed and TNF-« was measured by ELISA.
The cells were stimulated in 200 ~I of media so there would be enough
supernatant to test each in duplicate both undiluted and diluted 1:2. It was
important to lest samples diluted because the upper reliable limit of the ELISA was
3.5 ng/rnl TNF-ll and if a sample contained more TNF-ll than 3.5 nglml it would
not be measured accurately in an undiluted sample. Because the ELISA was
designed to test 50 [.Illwell, 100 J,llof undiluted supernatant was required to test
the sample in duplicate. The dilute sample was prepared by diluting 50 [.I of
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undiluted supernatant with 50 ~ I of culture medium. Thus. a lotal of 150 ~ I 01
undiluted supe rnatant was required. Thesupem atants from the non-st imulated cells
were only tested undiluted.
2.1.7 HLA-Typ lng
HLA·A, -6, -O, -DRand -DOtyping was done using standard complement
mediated cytotoxicity assays by two medical students , Christ ian Pugh and Ken
Power, as part of a another project.
2.1.8 Statfstlcal Methods
The coefficient of var iation for the ELISA was determined by the form ula:
Standard Deviation
, 100
Mean
The standard deviat ion and mean were calculated using the statistical
softw are InSt al (GraphPad. San Diego).
For HLA associations , secreted TNF ·a: leve ls were compared by Ihe
Mann·Wh itney test using the statistical software InStat.
2.2 RESULTS
2.2.1 Elisa Dev ,,}lopment
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This section describes the results for the development of the ELISA.
2.2.1A GAR ·H RPO Dilution
OD's were plolted against the dilut ion factor. The titrat ion plots were
generally very steep with a shallow portion somewhere in the middle (Figure 2.1).
The working dilutio n chosen was Ihe one which was in the shallow portion ot lhe
c urve. The working dilution was usually from 1:2500 - 1:4000. In the figure shown
it was 1:3000.
2.2.18 Coali ng Antibody Diluti on
The concentration of coating antibody chosen was Ihe one above which
h igher concentrations did not give a significant increase in 00 and ccocentrenoos
belowgave a significant aD decrease (FIg ure 2.2). Based on these results 2 ~glml
of coating antibody was chosen.
2.2.1C Secondary Antibody Ooncentrancn
OD's were plotted against rabbit anli·TN F·u dilution factor . A dilution of
1:300 was chosen because it was not in the steep section of the curve and the
ba ckgroun d was almos t zer x However, at 1:300dilution there was little differ ence
in 0 0 '5 between 10 nglml and 5 nglm l \j=igura 2.3). The upper limit of the ELISA
at this diluti on would Ihere lora be between 5 ng/ml and 10 nglm!.
2.2.10 Range of Sensitivi ty
5 1
The sensitivity range of the ELISA is 54 pg/ml to 7000 pg/ml TNF·a . At
54 pg/mllhe OD's are 2 to 3 times above background but below 54 pglml TNF· "
the OD's are at background levels. Above 7000 pglml the CUlVe reaches a
plateau. However. the useful range of the ELlSA for measuring TNF-tt is 3500
pglm l to 100 pglml because outside of this range the curve begins 10 plateau
(Figure 2.4).
2.2.1E Coeffic ient 01VariaUon
The coefficient of variation for the EllS" was less the 15 % . Figure 2.5
shows the variation in concentration for thecontrol sample that was calculatedfrom
the standard curves for 15 different experiments.
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Figure 2.1 : Sample titr ation curve for goat anti-rabb it-HRPO . The plat e
was coaled w ith both rabbit IgG (. ) and mouse IgG (e ).
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Flgure2 .2: Bind ing of mouse monoclonal an\i·T NF·1X to polyslyrenepla te
under different concentrations. The (.) shows the binding of the anlibody
to the plate by usinga goalanti·mouse·HRPO as labelling antibody. The
(e l showsthe binding ofgoat anti·rabbit·HRPO tathe m ousemonoclonal
anli-T NF-a 10 test for nonspec ific bind ing.
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. ibody, rabbit anti·TNF-« ,
e secondary ant I (.) and 12 3 . Titration of th 10 nglml ,e ), 5 nglm ,Figure .. . of rTNF-a ,
against 3 concentrations
nglml (a ).
55
. . .. .. 0: • • ft • •• , • • •••• I • • ' . "
Rgure 2.4 : Standard curves from the TNF-a ELISA run at six different limes.
Standard deviation bars showthe standard deviation for duplicate wells.
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/Figure 2.5 : Varialion between runs of the TNF·a ELI SA. Th e dala are
derivedfrom runninga sample of2500 pglml rTNF-« each lime andthen
calculatingthe concentration fromthe standard curve.Thesevalues were
then used 10calculate the coefficient of variation.
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2.2.2 Variat ion In Secreted TNF-a Levels in xi.t!:Q
Per ipheral blood mononuclear cells from young males show large
inlerindividua l diflerencp.sin the levels of TNF-a secreted whenstimulate d with20
~g/m l LPS for 3 hours. The range for thegroup was 157.7 pg/ml lo 3900 pg/ml
ina frequency distribution that wasskewed to theleft (Figure 2.6). The meanfor
thegroup is 1213.9 pglml with a standarddeviation of 673.6.
Becauseme distribution Is skewed to the left, tha high secretors stand
out. Thisgroup isalso outsideof apopulation defined by themean i 2 x standard
deviation(2SD = 1347.2). The low sec re'ors however. arewithin thelimits sal by
Ihe mean i; 25 D.
2.2.3 Stable Interind ividual Differences
The levels of secretedTNF·a. infour malesubjectsthat weretestedfrom
2to 4 limesare stable (Table 3) . The standard errorswere low for SP, LS and DB.
DB and VJ were repeated only once. Althoughthe second reading for VJ was
almost double the first, theamounl of TNF-a secreted is still at thelower end of
the range fo r thepanel of males.
Secreted TNF·a levels were notas stablefor thefema les. The standard
errors were high for all B females tested (Table 4) with a variation range from
28.5% to 100.5%.
58
Figu re 2.6 : Frequency Dist ribution of TNF- (t Secretion in 72 Heallhy Males 20 -
30 Years O ld.
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Table3: Stable lntra-indivldual tevels of TNF-(t Secretionby4 Individuals Tested
from 2 to 4 Times.
Subject TNF-. (pg/ml) Mean SD
2 3
SP 1113 1400 1191 1477 1310.3 151.6 (11.6%)
LS 3358 3567 3000 3308.5 286 (8.6%)
DB 1083 1032 1051 36 (3.4% )
VJ 432 848 640 293 (44.8%)
--- - - - - - - - - - - - - - - - - - - - - -
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Table 4 : Variation in Secreted TNF-u le vels byPBM C from 8 Pre-menopausa l
Females Tested 3 to 4 times.
- --- - - - - - - - --------- --- -
Subject TNF·. (pg/ml) Mean SD
2 3 4
14 85.5 700.5 7 11.3 .. 967.7 448.4 (46.3%)
3 19.5 an.5 1075.6 - 690.9 378.2 (54.7%)
7 16.8 1507 1788 699 1177.7 554 .5 (47.1%)
576.2 1627 413.2 62.3 669.7 673.3 (100.5%)
11 19.5 380.5 648.9 .. '116.3 374.1 (52.2%)
1187 2563 1644 .. 1798 700.8 (39%)
42 4 6 14.5 669.2 1573 820.2 5 12.8 (62.5%)
870.1 1369 920 1550.5 1177.4 335 (28.5%)
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2.2.4 HLA Associations with Secreted TNF-iX
HLA ·DR data are available for on ly 49 of the 75 males in the study
group. The HLA·B data are nearly complete, wi th 62 individuaIs typed. The
complete results are shown in Appendix A. Th e data were analyzed for HlA·DR2,
-DR3, and · DR4 individuals (Figure 2.7) and only for those HLA-B groups w here
m 5, or, in other w ords, only for those HLA- antigen s which were present in 5 or
more individ uals in the sample tested. Eight gr oups we retested forHlA-B antigens
(Figure 2.B). In each case pairwise compar isons were made between leve ls 01
TNF·a in, for example, n az-posnv e and DR2-negative individuals, HLA-B8
positive and HLA-8 8 negative individuals, et c. The Mann·Whitney Test was used
for these ana lyses.
H LA-DR2 wasnot found to be associated withlow TNF· a secretion. The
mean TNF-a secreted by HLA-DA2 individuals was higher than that of non· HLA·
DR2 Individ uals (Figure2.7) butnot significantly (p=O.16)(Table 5). The data were
also analyzed alter removing from the analysis the DR2 individuals who were also
DR3 or DR4. Again there was no statis tical diff erence between those DR2
individuals and non·DR2 individuals (p=O.12) .
T he HLA-DR3subjects had lower mean T NF-a secretion than ncn- Dga
subjects as well as lower than the HLA-DR2 subjects (Figure 2.7). When the DR3·
positive an d OR3-negative subjecls are compa red by the Mann-Whi tney tes t , the
difference between the two groups is signif icant (p=O.014) (Table 5
62
). The probab ilit y remained bar ely signi ficant aft er correction for the nu mber of
comparisons made in the HLA-DRanalys is (0.0 14 x 3 comparisons = 0.042). The
results suggest Ihat individuals wilh the HLA·DR3 antigen show lessvariability and
lower levels of T NF-a secretion than other individ uals in thesam ple.However, the
number ofHLA-OR3+ individuals is relative ly small (n=10) and th ere was onlyone
HLA-DA3 homozygous Individual.
There was no aesoctatcn fo und betwe en HLA-Banti gens and levels of
TNF-a secretion . HLA-B5 indivi duals ha d thelow est mea n secreted TNF-a levels
but the differe nce is not significant w hen com pared to the non·B5 in dividuals
(p=O.4) and on ly 6 of 62 were HLA·B5 positiv e. HLA-B17 ind ividuals had the
hlghesl mean secrete d TNF-a levels but again the diff erence is nol s ignificant
when compared 10the non-B17 individ uals (p=0.44 ).
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Figu re 2.7 : HLA·DR Distribu tion and TNF- o: Secretion in Healthy
Males(n=49) . Each point represents a single individual and the
horizontalbars mark theaverageTNF-« secretion for lhegroup.
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Figure 2.8 : HLA·B Distribution and TNF-a Secretion in Normal
Males (n",S2). Each point represents a single individual and lhe
horizontal bars mark the mean TNF-a secretion for the group.
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Table 5:Analysis of HLA·OR associations withsecreted TNF-a:from healthymales
HLAClassII Numberof
Subjects
Mean
TNF· a:
(pg/mll
Std.Oev. Mann-Whitney
p value
DR2 (non3 or 4) 11 1446 590 p=O.16Non DR2 36 1244 637 p=O.12DR2 13 1423.5 543.8
OR3 (non OR2) 10 927 179.5 p=O.014Non OR3 39 1389.7 647.3
- - -------- - - ------ - - --- - -
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2.3 Discuss ion
This chapter has shown that there is variability in levels of TNF-IXsecreted
by PBMC from young males under the experimental conditions used and that there
is a possible assoclatlon of low TNF-« secretion and HLA-DR3. The levels of TNF·
IX secreted are relatively stable in five of the males that were tested more than
once.
2.3.1 In ter-individual Vari ability in Secre ted TNF-a l evels
The results 01this analysis has confirmed those of Jacob~ (1990) and
Molvig~. (1988) that males have stable interindividual differences in TNF-a
secretion, although experimenta l conditions were different in the three sets of
experiments.
Jacob gU1 (1990) arbitrarily divided their panel of subjects into three
groups, high, medium and low TNF- IXsecretors. Sachs~(1990), however, in
PHA stimulated PBMC experimen ts said that for TNF-« levels, subjects could not
be statistic ally divided into high and low secretor grou,...s. They had used the
standard skewness test for norma lity and then the likelihood ratio test to see if two
populatlons. high and low secretore. existed.
This would imply that thare are not two groups, high and low secretors, hut
simply a wide variation about the mean. An individual , therefore , on the high or low
end of the distribution would stay that way when sampled again. This variability in
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the distribution could be due 10 (I) differences, or polymorphisms in the TNF-o:
gene which affect leve's of expression, (ii)differences in secret ion, (iii) differences
in kinetics which a single time sample would not dete~t , (iv) differences in relative
numbers of TNF-o: secreting cells. or (v) differen.c,?s in the rate of disappearance
of TNF-a from the supernatants by binding to receptors on cells or degradation.
2.3.2 Stability of TNF-o: Secretion by Males
Healthy young males were chosen as the study pane l for TNF-o:secretion
because the cells would not be influenced by cyclical hormonal changes. It has
been recently reported that TNF-(t secretion ill. vitro by PBMC from pre-
menopausal females has been shown to fluottlate when sampled randomly while
TNF-o:secreted by males does not (Jacob gtjl11990). The results of our analysis
confirm those of Jacob &slL(1990) that TNF-a secreted by PBMC from metes is
stable but TNF-o: levels from pre-menopausal females fluctuate when tested
weekly throughout a 4 week period.
2.3.3 Possible HLA Assoc iat ions with Secreted TNF-a Levels
Associations between varying levels of secreted TN F-a and HLA alleles
would suggest a polymorphism or polymorphisms in the TNF-u gene or promoter
regions that affects TNF-a expression. Because the TNF-a gene is found within
the MHC region one might expect these polymorphisms to be inherited along with
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the particular HLA allele. If this were the case most individuals with the same HLA
alleles might be expected to secrete approximately the same amount of TNF-a, if
there were no other factors influencing TNF-o: secretion.
The leek of association between HLA-DR2 and low TNF-a: is contradictory
to some previous reports. Jacob et at. (1990). Brendtzen~. (1988) and Molvlg
U . (1988) aUreport of finding an association between HLA-DR2 and low TNF-«
secretion in males. High TNF-o: secretion was also associated with HLA-DA3 and
DR4 in one of the reports. However. a second paper by Molvig et at (1990) did not
find any associations with HLA-DR alleles and TNF-a secretion when purified
monocytes instead of PBMC were used and Sachs~. (1990) did not find any
associations when PBMC were used. Molvig did suggest that the lack of
association with HLA-DA2 may be due to the small number of DR2 positive
individuals in that study (0:5). On the other hand they say that the DA2 and DA4
homozygous individuals had very similar TNF-a: and IL-l P secretory levels and the
DR2,4 heterozygous individuals had the lowest secretion levels. This finding also
contradicts the Jacob data. They suggest that DA3 and DR4 are high secretors
and are dominant. In the Jacob data most DA2,3 and DR2,4 heterozygous
individuals were high secretors.
No studies, including this one, have demonstrated associations between
HLA·B and TNF· « secretion. This lack of association of HLA·B alleles wilh TNF-o:
secretion is interesting because the HLA-B locus is closer to the TNF-« locus than
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is HLA·D A. One might expect a greater degree of linkage disequilibrium between
HLA·S alleles and putative TNF-a gene variants than between HLA-DR and TNF·
a. One possibility, so far without evidence, is that another gene or regulatory
region near the HLA-DR gene is involved in the regulation of the TNF·a gene.
If particular HLA·DR alleles are associate with putative high/low TNF·a
expression, one might expect to find markers at or near the TNF locus. There is
in fact a Ncct RFlP at the TNF locus thaI is dial1elic, a 5.5 kb allele (TNFS01)and
a 10.5 kb altele (TNFS"2) (Pociot !'tl..£lJ. 1991; Fugger~. 1989). Pociot and
collegues have shown that TNF·IX secreted from LPS stimulated monocytes is
lowest in TNFso1 homozygous individuals and highest in TNFS"2 homozygous
individuals. The heterozygous individuals had intermediate secretion levels. Beth
Jacob and Poclot however, could find no association when unfraclioned PBMC
were stimulated. An interesting point about the Ncol RFLP is that the high secretor
TNFso2 allele is associated with HLA-DA2 and TNFS"1 with HLA·DR3.
More recently, mlcrosatellite mapping has allowed for the detection 01 a
greater number of variants in the TNF genomic region. Three polymorphic
mlcrosatelllte regions have been identified : TNFa and TNFb 3.5 kb towards HlA·B
from TNF- ~ and TNFc in the first intron of TNF'~ (Nedospasov~. 1991).
Associations have been reported between alleles or the TNFa region and TNF-tt
secretion. In a study where monocytes were stimulated with 250 pglml LPS for 20
hours the strongest associations were between the TNFa2 allele and high TNF·a
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secretion and between the TNFa6 allele and low secretion (Pociot U. 1993).
TNFa data are available for the male study group (Michelle Simms,
personal communication). Eight of the ten DA3 individuals are TN Fa2, the "high
secretor" associated allele in the Pociot study. However, TNFa2 also occurs in
16139 of the DR3-negative individuals tested.
The use of cells from individuals homozygous for both the DR and
microsatellite alleles would probably provide a better understanding of associations
with TNF-a expression. Using heterozygous individuals is problematic because if
there are linkages of TNF-a gene express ion polymorph isms to HLA alleles and
microsatellite variants, it Is difficull to ascertain the contribution that each TNF-«
gene variant may make to the total amount of TNF-a secreted. A low responder
gene may be masked by a high responder gene.
The associations between TNF' a secretabllity and genetic markers near the
TNF-a gene may net be a simple matter of polymcrphlsms of the TNF-a gene.
From cell stimulation 10 the time Ihe secreted protein is measured there are many
steps that can affect the amount of protein that is detected in the supernatant.
After LPS stimulation, a receptor is first activated and a signal sent to the nucleus
l0 ,sctivate the TNF-a gene to transcribe mRNA. This is followed by production of
a polypeptide which is transponc d to the membrane. cleaved and secreted . Genes
located in or near MHC genes could contro l some of these events. The association
of HLA-DR alleles and lack of association with HLA-B alleles with TNF-« secretion
7 1
might, in fact, point to teeters other than a variant of the TNF-a gene.
Another factor that cannot be overlooked, especially in long term
cultures of PBMC, is the rate of TNF·u degradaticn. TNF·u is degraded or
removed from the supernatants by binding to TNF receptors. The amount of TNF·
a detected in the supernatants at a given lime is a function of both secretion and
removal.
One potentially important observation about the published investigations is
that no two experimental systems were exactly alike. There were differences in the
type of cells used, choice of stimulants and incubation limes. The different
incubation times and the use of different stimulants may contribute to the different
levels of TNF·a secretion observed. We do know for example, thai LPS and PMA
activate cells in different ways to produce TNF-a . LPS requires a receptor while
PMA does net. It is possible that the kinetics of secretion varies from individual to
individual and likely that the kinetics of secretion is effected by the type and
quantity of stimulant used to induce TNF·a secretion. Experiments in the next
section were designed 10 address some of these questions.
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Chapter 3
Kinetics of TNF· (X Secretion
PBMC from five individuals with different TNF·a secretion levels as defined
using the experimental protocol in Chapter 2 were selected for further study. The
patterns of TNF-" secretion over time were investigated using three different
stimulation protocols; 20 IJ.glml LPS, 1 nglm! LPg and 1l-lg/mlConcanavalin A plus
2 nglml PMA.
3.1 Methods and Materials
3.1.1 Selection of Subjects
Five male subjects were chosen from the study group in chapter 2. They
were chosen to represent high. medium and lowTNF-a secretarsbased on the 2
hOUT, 20 Ilglml LP$ stimulation of PBMC as described.
3.1.2 Preparation of Cells
PBMC were Isolated from fresh blood as described in chapter 2.
3.1.3 Induction 01 TNF-o: Secretion
Stimulation of the PBMC was the same as described in seclion 2.1.3 with
the following changes. Three different stimulants were used to induce of TNF· "
secretion. LPS was used at 20 ~g/ml nod at 1 nglml and a mixture of 1 ~glm l
Concanavalin A (Sigma, 51.Louis, MOl with 2 ng/ml PMA(Gibco/BRL, Burlington,
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ON). The cells were stimulated under these conditions for 3, 6. 9. 24, and 53
hours.
3.1.4 Determ ination of Secreted TNF- o: Conc entration
TNF-o: was measured in the supernatant of each experImental and control
sample using the TNF-o: ELISA described in section 2.1.2.
3.2 Results
3.2.1 Kineti cs of TNF-o:Secretion for 3 Diff erent Stimulat ion Cond itio ns
The kinetics of TNF'a secretion differ for each of the stimulation protocols
used. Stimulation with 20 l1g1ml LPS resulted in peak secreted TNF-a at 3 to 6
hours and declined thereafter unlilthe end of the experiment at 53 hours (Figure
3.1). For 3 subjects, at 53 hours the TNF-a levels had dropped to <100 pglml .
near the sensitivity limit of the EUSA. Stimulation with 1 nglml LPS resulted in a
peak TNF-a level at 3 hours which had started to decline by 6 hours (Figure 3.2).
By 53 hours all subjects were secreting <100 pglml. Stimulation with ConA/PMA
shows a contrasting pattern of TNF-a secretion to that of LPS. TNF-a levels were
lowest at 3 hours and continued to increase unUlthe end of the experiment at 53
hours (Figure 3.3).
Although the secretion patterns of TNF-o:are similar when TNF-cxsecretion
is induced by 20 I!glm l and 1 nglml LPS, there are several dilferences. At 1 nglml
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LPS, the maximum amount secreted is less than with 20 I-Lg!ml LPS. The
maximum with 1 nglml LPS was 1050 pglml TNF-a but 4900 pglml TNF-a with
20 ll glml LPS. Also, the highest is at 3 hours or earlier with 1 nglml LPS but at 3
to 6 hours for stimulation with 20 I-Iglml LPS.
3.2.2 Differences in Clas sification of "high" and "low" TNF~a Secretors under
Different Stimulat ion Condi tions
Although all 5 subjects have very similar TNF-a. secrelion patterns within
each of the stimulation conditions, they differ in the relative amounts of secreted
TNF· (t under different slimulalion conditions. With 20 I-Ig!ml LPS for 3 hours. LS
secretes approximately 3 times more TNF-a than SP or DB (Figure 3.4). However
at 1 ng/ml LPS for 3 hours, LS secretes less than half the amount of TNF· a as SP
and DB. LS has an 87% reduction in the amount of TNF-a secreted when the
lower LPg concentration is used. DB however, has no reduction and SP drops by
30% .
A similar situation is seen when 20 I-Lglml LPS for 3 hours is compared with
ConAlPMA stimulation for 53 hours (Figure 3.5). With 20 I-Iglml lPS, LS secretes
3 limes more TNF-« than SP or DB. With ConA'PMA howeve r, both SP and 08
secrete more TNF-a.than LS. SP and DB have a 4·fold increase in the amount of
secreted TNF-« with ConAiPMA stimulation compared with 20 l1g1ml LPS
stimulation but there is no increase for LS.
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Figure 3.1 : Kinetics of TNF-a Secretion by eBMC
from 5 Hea lthy Males. Cells were stimulated with 20
~g/ml LPS
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Figure 3.2 : Kinetics of TNF·" sec retion by PBMC from
5 Heanhy Males. Cells were stimulated with 1 ng/ml
LPS
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Figure 3.3 : Kinetics of TNF·a Secretion by PBMC
from 5 Healthy Males. cells were stimulated with 1
}1g1ml ConA + 2 nglml PMA
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Figure 3.4 : Comparison01the effects of different concent rations 01LPS on
TNF-ll secretion by PBMC from 3 males. Stimulalion was f()( :; hours.
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Figure 3.5 : Relative differences in levels of TNF·[l secretion by PBMC from
3 males when stimulaled with 20 l1g!ml LPS for 3 hours and ConN PMA for
53 hours
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3.3 Discussion
3.3.1 Kinetic Diff erences
The kinetics of TNF-a secretion were investigated for several reasons. First.
to determine. if under a given stimulation protocol, cells from all individuals
reached peak TNF-a secretion levels at approximately the same time. This would
answer the question as to whether "high" or "low"' secretor individuals actually
produce the same amount of TNF-« but reached their maximum levels at different
limes . Secondly , LPg and PMA have been used by many investigators 10 induce
TNF-a secretion by different cell types. Jacob~1. (1991) used Can AlPMA 10
stimulate TNF-a secret ion and to define associations between TNF-a secretion
levels and HLA-DR alleles. Differences in experimental conditions may explain the
conf licting results obtained by others as discussed In Chapter 2. Thirdly. there has
been some crit icism in the literature about the use of high concentrations of Lp g
because levels as high as 20 Ilglml are unlike ly to be reached !!J. vivo even in
pathologica l conditions. The kinetics of two concentrations of LPg were compared
to determine if LPS dose affected individual differences in TNF·a expression.
It is quite clear that the kinet ics of TNF-a secre tion are very similar among
the 5 subjects for each the 3 stimulation protocols. The amounts of TNF-a
secreted by different subjects differ but the pattern of secretion during the 53 hours
is the same. For a given stimulation protocol they all peak at the same time or
decllne at the same time.
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It is important to note that, although these experiments were designed to
monitor the kinetics of TNF-o; secretion, and this language is used throughout this
Chapter, the ELISA measures TNF-a detectable in the cells' supernatants after
stimulation. As described in Chapters 1 and 2, the amount detectable at any time
represents a balance between TNF-a: secreted and TNF-a: degraded or removed
by TNF-a receptors on the cells or in solution. Thus "klnettcs of TNF-a: secretion-
is a convenient, but not totally accurate, expression of what is actually happening
in the experiment.
The highest level of TNF-a using 20 ~g/ml LPS wes found at 3 to 6 hours
and using 1 ng/ml LPS it was at 3 hours for all 5 subjects tested. Lonnemann ~
m.(1989) also reported peak LPS induced TNF-a: secretion at 3 - 6 hours but for
purified monocytee, not PBMC. This would suggest that the primary source of
TNF-a: in our LPS experiments is monocytes. There are no reports of TNF-a:
secretion by T- or B-lylT';.'.tocytea stimulated with LPS. One can only speculate as
to the role the lymphocytes may play in the accumulation 01 TNF-a in the
supernatants. Lymphocytes are known to express TNF receptors and probably
contribute in the removal 01TNF-a from the supernatants.
The kinetics of TNF·a: secretion are very similar for both concentrations of
LPS tested. The main difference is the amount of TNF-« secreted. With 20 lJg/ml
LPS the highest levels found are more than four times the highest levels with 1
ng/ml LPS. Molvig~. (1988), using LPS concentrations from 12.5 pg/ml to
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0.25 Ilglml to stimulate monocytes and harvesting supernatants at 20 hours, did
not observe any increase in secreted TNF-o: levels with LP$ concentrations over
500 pglml. Lynn gU!. (1993) on the other hand, using the monocyte cell line
THP-1, reported a continued increase in secreted TNF-a lovels with increasing
LP$ concentrations as high as 10 I-Lglml, which was the highest concentrauon
tested. Because our data are for only two LPS concentrations we do not know if
some concentration lower than 20 Il g/ml LPS, but higher than 1 nglml would
stimulate maximum TNF·a secretion. However, it should be noted that our lowest
concentration of LPS was two times higher than the highest above which Molvig
did not observe an increase in secreted TNF·o: levels.
It was somewhat surprising to find the 20 hour LPS stimulations in Ihe
literature that describe TNF-o:variation and HLA associations in light ofour kinetics
data as well as that published by Lonneman et al. (1989). At 20 hours. particularly
for low LPS concentrat ions, most of the TNF· a has diminished to the point where
there is very little variation among the individuals tested.
LPS activates monocytes to secrete TNF-a by binding to specific receptors
on the cell surface. The differences in amounts of TNF-a secreted under
stimulation with different concentrations of LPS may be due to differences in the
number or type of receptors being bound by LPS. For maximum TNF·a secretion,
receptors may have to be saturated with LPS.
The difference in kinetics between LPS stimulation, regardless of
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concentration, and ConNPMA stimulation Is quite dramatic, LPS stimulations result
In rapid TNF-o: release with rapid disappearance from the supernata nts.
ConAlPMA stimulations result in slow TNF-« release at 3 hou rs which Increases
to the end of the experime nt at 53 hours,
LPS binds tns-receptcre and these receptors are foun d on monocytea.
PMA does not bind receptors but Instead iniliates cell ular activity by acllvating
protein kinase C directly and therefore can potentia lly Induce TNF-o: secretion In
a broad range of cells, Thus, TNF-a Induction by LPS and PMA may be two
dille rent phenomena affecting different popula tions of cells, We do know that both
monocytes (Hass et at 1991) and lymphocyt es (von Fliedner ~, 1992) can be
Induced by PMA to secrete TNF-a and the secretion can be sustained for 48 - 72
hours.
There may even be different regulato ry factors in different cells that may
account for the differences in TNFo: secretion between LPS and ConNPMA. A
recent review (Aao 1994) discussed a transcripUon factor , NF-AT, that is activated
by increase calcium fluxes. This factor is found in T cells and activates the TNF-«
gene as well as other cytok ine genes. Crosslinking TCRlCD3 and Fey receptors
leads to calcium mobilization in lymphocytes, LPg activation of mcnocytes through
CD14 however, is mediated through protein kinase C, not calciu m fluxes. NF-AT
is also found in monocytes but its existence opens up the poss ibility of the
existence of a number of regulatory factors that may influence TNF-a secretio n
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differently depending on the individual and the stimulant.
The addition of Con A to the culture with PMA results in increased TNF·«
secretion over PMA alone (Jacob~. 1990). This adds to the likeltlood that
lymphocytes are also producing TNF-a or contributing in some way to the
production of TNF-" . ConA is a known T-cell mitogen. stimulating the proliferation
of T-cells. If T-cells are proliferating in the culture the increased TNF-a could be
due to an increase In the number of cells secreting TNF-a..
The kinetic dilferences between LPS and ConA/PMA induced TNF-a
secretion may also be attributed to the involvement of LPS receptors in another
way. LP$ receptors may become unresponsive after prolonged LPS exposure.
This would mean that when LPS first binds the receptor there is a signal generated
to produce TNF-a. Alle r prolonged exposure the cell becomes LPS tolerant in that
the signal transduction pathway shuts down and TNF- a production stops even with
continued exposure to lPS. PMA however I by by·pass ing the receptor and
activating PKC directly can generate the signal to continually produce TNF-a.. In
tact, it has been shown that peripheral blood monocytes become unresponsive to
LPS after prolonged exposure but these lP5-uoresponsive cells are not
unrespons ive to PMA (Matic & Simon 1991).
PMA also downregulate s the expression of TNF receptors on cell surfaces
(Gatanaga §U!. 1991). These receptors bind TNF·" to the cell or can be shed into
the medium and bind TNF-" there. The result in either case is a loss of TNF-ll
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from the supernatants. If the number 01receptors that can bind and remove TNF-a
from the supernatants is reduced. there would be an expected increase in the
amount of TNF-" accumulallng in the supernatants.
We do not know if the antibodies used in the ELISA to detect TNF-a can
bind TNF-" -receptor complexes. The disappearance of TNF-a from the
supernatants from 6 - 53 hours suggest they do not because if the antibodies do
bind TNF-" -receptor complexes then shed receptors would have no affect on the
detection of TNF-a in the supernatants. This can be tested because TNF-a
receptors. known as TNF-a binding protein, are now available comme rcially. TNF-
«-receptor complexes could be prepared and tested in the TNF-a ELISA.
3.3.2 Differences In relati ve amount s of TNF-a secreted among Indi vidual s
The differences in amounts of TNF-a secreted under different stimulation
conditions by different individuals relat ive to each other was quite surprising. It was
assumed that if an individual was a "high" secretor relative to another using a
given inducing agent, it would also be true with a different inducing agent. The
"h igh~ and "low" secretors in the work by Jacob U . (1991) and Molvig ~.
(1988) may very welt only exist under those conditions.
The change in the amount of secreted TNF-a by LS relative to SP and DB
at the lower LPS concentration resulted in LS becoming a low secretor relative to
SP and DB. There is very little change for SP and DB. LS also becomes a tower
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secretor than SP and DB when ConNPMA for 53 hours is used to induce TNF-"
secretion. In [his case LS does not changecompared with the 20 ~glml LPS
stimulation for 3 hours but Instead SP and DB have increased levels. II should be
noted that the ConAIPMA 53-hour protocol is similar to the one used by Jacob ~
;!h (1991) .
The reason why one individual may be a -high- secretor with one LPS
concentration but be a -low" secretor relative to the other individuals when
stimulated with a different LPg concentration may be due to individua 1differences
in the types and numbers of LPg receptors. CD14 appears to be the primary LPS
monocyte receptor that binds LPS under low LPS concentrations to induce TNF-«
secretion . Under high LPg concent rations other l PS receptors mey play an
important role in TNF·« induction (Lynn ~ ID. 1993). These recepto rs may be jow
affinity receptors and require higher LPS concentrations. Thus, at high LPS
roncentrations, bolh CD14 and oth9f, towallinity, receptors may be act ivated. OM
might speculate that LS, for examp le, who is a relatively hi~ producer at a high
a LPS concentrati on but low at a low LPS concent ration has lower levels of C014
exp ression andlor higher expression of other low allin ity receptors than some of
the other individuals in the sample .
The differences that exist when cnmparing LPS and ConA/PMA stimulanons
may occur for a number of reasons. One is the initial proportion and the Can A-
Induced proliferati on of T-cells In the 53 hour ConAlPMA cultures. The PBMC of
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SP and DB may contain a relatively higher proportion of TNF-« -producing 'r-cens
than LS. Another possibility could be a greater degree of downregulalio n of TNF
receptors by PMA for SP and DB. If the cells were expressing fewer receptors less
TNF-« would be removed from the supernatants allowing for a greater
accumulation. The experiments in Chapter 4 were designed to further investigate
the first of these possibilities. that differences ill levels of TNF-u accumulating in
the PBMC supernatants arise from ditterences in the relative numbers of different
sub-populations of cells.
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Chapter 4
Cell Phenotypes and TNF-a Secretion
This chapter describestwo sets of data collectedby flow cytometry. The first
describes a double labelling flow cytometry protocol, and the development of the
protocol to determine cytoplasmic TNF-" and cell phenotype simultaneously. The
second is differential PBMC phenotype counts of the male study group to
determine if there wereany correlationsbetweenthe numberof cells 0' a specific
phenotype and the levels of TNF· (X induced by PBMC stimulations.
4.1 Methods and Materials
4.1.1 Reagents
4.1.1A Fixatives
(1) 0.5 % Paraformaldehyde
500 mg paraformaldehyde(BDH, Toronto )
100 mls PBS
Paraformaldehyde Is dissolved by heating the solution
(2) 4 % Paraformaldehyde, pH 7.2-7.4
4 9 paraformaldehyde
100 mls PBS
Dissolve paraformaldehyde by healing
Adjust pH to 7.2 - 7.4 with sodiumhyroxide
Store at 4°C
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4.1.18 Antibodies
(1) F'urified Normal Goat Ig (Ceda r lane, Mississauga )
(2) Polyclonal Rabbit anti-keyhol e timpet hemocyanin (Sigma, St. Louis)
(3) Polyclonal rabbit antl-TNF·o; (serum) (Gift from Dr. Steve Foster , ICI
Parmaceuttcare. Cheshire, England)
Purilicalion described in sect ion 4.1.2
(4 ) Purified Monoclonal anti-TNF-a conjuga ted with FITC (R & D Systems ,
Minneapo lis)
(S) Purified Polyclonal Rabbit anti·TNF-a (Ca lbiochem , Palo A lto)
(6) Purified Polyclonal Rabbit ant i·TNF -a (Bio-Design , Maine)
(7) Anti-C014 (AMAC, Mississauga)
Binds C014, a surface molecule on monocytes
(8) Anti-COB (AMAC, Mississauga)
Binds C08, a surface molecule on cytotox ic T- cetls
(9) Anti-CD4 (AMAC, Mississauga)
Binds C04, a surface molecule on helper r -eefs
(10) FITe conjuga tes of anti-CD14, anti-CD4 , anti-COB, anli-C 03 (T cells)
and anli-C D45RO (Memory Helper r-cenejwere purchased from Sigma, 51.
Louis . These antibodies were used for differentia l celt counts.
(11) Phycoerythrin-conjugated goat enu-rabblt Ig (Sou thern Biotechnology,
A labama)
(12) Phycoerythrin-conjugated goat anli -mouse Ig (Southern Biotechnology,
Alabama)
4.1.1C Othe r Reagenfs
Monensin was purchased from Sigma , 51. Louis. Saponin was purchased
from le N, Mississauga.
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4.1.2 Purif ication o.Rabbit antl·TNF·o:
The IgG component of the serum provided by Dr. S. Foster was purified
with the Affi-Gel Protein A MAPS II kit (Bio-Rad, Mississauga, ON). The protocol
follO'....ed was as outlined in the instruction leaflet provided.
A 1 cm x 10 em Econo-Oolumn chromatography column (Blo-Had] was
packed with 1 ml of the Affi-Gel Protein A agarose beads. One rnillilitre of bead
solution with 2-3 ml of binding buffer (provided as part of kil) was added 10the
column with the 110wturned off until the beads settled to the bottom. To wash and
equilibrate the beads. the flow was turned on and more binding buffer was added
to the column with a Pasteur pipel to maintain a constant flow rate and to prevent
the beads from drying out. The pH of the effluent was monitored until it reached
the pH of the binding buffer (pH 9.0). Approximately 5-6 ml of binding buffer had
been added.
A 1 ml aliquot of the serum sample was diluted wilh 2 ml of binding buffer
and applied to the column. The effluent was collected in a tube and reapplied twice
more 10the column. After sample loading, the column was washed with binding
buffer, approximately 15 ml, until the protein concentration reached baseline. The
protein concentration in the effluent was monitored with a Bin-Had Econo-System
UV monitor (260 nm) and chart recorder.
Bound IgG was eluded using the elution buffer providad with the kit. Elution
buffer was added slowly to Ihe column and the protein content in the effluent
9 1
carefully monitored. Al the moment protein was detected in the effluent it was
collected in a separate tube until lhe protein content started falling to baseline .
Approximate ly 4 ml were collected. The pH of the elution buffer was very low (pH
3.0) so the sample was collected in 0.5 mls of 1M Tris HCI at pH 9.0 to neutralize
the eluate and minimize the lime the antibody would be exposed to extremely low
pH.
To remove the elution buffer, the sample was dialysed overnight at 4°C
against 2 litres of PBS. The PBS was changed 3 limes.
The purified antibody was filter sterilized with a 0.22 micron Millipore filter
(Fisher Scientific. Montreal) and the concentration measured with the Sia-Rad
Protein Assay Kit (Bic· Rad, Mississauga, ON). The antibody was aliquoted at 0.5
mglml and stored at -70°C.
4.1.3 Double Stain ing for Cytoplasmic TNF·a and Cell Phen otype
The choice of subjects was based on levels of secreted TNF· " determined
previously . Two high. one moderate and one low TNF-" secretor were selected
based on their willingness to frequently donate blood samples.
4.1.3A Induction of TNF-«
One 10 ml vac utainer tube (Becton Dickinson. New Jersey) with acetate-
citrate-dextrose (ACO) as anti-coequlant was used to coilect approximately 10 mls
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of blood by venipunctu re. Peripheral blood mononuclear cells were purified as
described in chapter 2 and resuspended at 1 x 10&/ml in culture medium.
The cells were put inlo wells of a sterile, 6-well flat boltom Falcon tissue
cullure plate (Fisher Scientific, Montreal). All the cells for each stimulation protocol
were put into a single well. For example, if cells stimulated with LPS were to be
labelled with four different combinations of antibodies for surface markers. and
cytoplasmic TN p-e. then 2 million cells were put into one well to be stlrnutateo with
LPS. Two million would have been required because the labelling and subsequent
analysis were done at 500 000 cells per tube. The plates were then inr.ubated at
overnight at 37°C in a CO2-incubator.
The following day the cells were transferred to 5 ml or 15 ml sterile
centrifuge tubes and centrifuged at 800 x 9 for 10 minutes. Fresh cullure medium
with 3 IlM monensin was prepared both with LP5 at 20 Ilglml and without LP5 .
A stock solution of 3 mM monensin was first prepared by dissolving 10.3 mg
monensin in 5 ml absolute methanol and then diluted to 3 IlM by adding 10 II I of
the stock to 10 mt of culture medium. The old supematants were discarded by
inverting the tubes and the cells were resuspended in the fresh medium, put back
Into the same wells of the a-well plate and incubated at 37°e for 1 hOur.
Using a rubber policeman sterilized in 95 % ethanol, the wells were scraped
to dislodge adherent cells. Itwas very important to do this because monocytes, the
primary TNF-a producers, are adherent to plastic in culture. The cells were then
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transferred to sterile 5 ml centrifuge tubes and washed twice with sterile PBS.
Washing was done by centr ifuging the cells at 800 x g and resuspending in several
mlllllitresof PBS.
In addition, cells were stimulated as described in Chapter 2 and secreted
TNF-« measured by ELISA to determine if the cells were producing TNF-« .
4.1.38 Fixa tion and Permeab ilization
After the final wash, the cells were centrifuged and 4 % paraformaldehyde
in PBS was added to fix the cells at a concentration of 1 x 101/mJon ice for 10
minutes. The paraformaldehyde had been previously chilled 10 4cC before use. All
subsequent incuba tions were on ice with pre-cooled reagen ts and centrifugation
in a 4cC refrigerated centrifuge. The cells were washed 3 times with cold PBS,
The cells were permeabi1ized by incubating the cells for 30 minutes on ice
in 1 % saponin in PBS atl x 107ce lls/ml with 15 % normal human serum to block
any non-specific protein binding sites. Normal human serum (NHS) was derived
from severa l healthy donors, Inactivated at 56cC for 30 minutes , pooled and stored
at ·20 cC. The cells were washed 3 times with 0.1% saponin-PBS .
For the last wash, the cells were resuspended in 0.1% saponin-PBS all x
10'/ml and transfe rred to a round bottomed 96-well plate. They were transferred
at 500 IJVwell. each well receiving 500 000 cells. For example. 2 million LPS
stimulated cells that would be labelled four different ways would now be equally
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distributed among lour wells of the plate. The plaia was then centriluged at 800
x g and the supernatant removed by inverting the plate.
Fe receptors(FeR) andany further non-specific binding sites thatcould bind
immunoglobulin were blocked with normal goat immunoglobulin. The cells were
incubated with 50 J.I! of 100 J.lglml goat Ig in 0.1% saponin·15% NHS-PBS for 15
minutes on ice. The cells were weshed 3x with 0.1% saponin-PBS by adding 200
uttc each well and Incubating for 10 minutes on ice before centrifugation.
4.1.3C Detect ion of Cyt oplasmic TNF-a
Cytoplasmic TNF-a was detected by an indirectmethod. The cells were first
Incubated with 100 J.l1of primary antibody al 15 J.lg/ml in 0.1% saponin-15% NHS-
PBSon icefor 30 minutes. The primary antibodies werepolyclonal rabbit anti-TNF-
« and poIyclonal rabbit anti·keyhole limpet hemocyanin (anti-KLH). The polyclonal
rabbit anti-TNF-a was a 9ilt from Dr. Steve J . Fosler at ICI Pharmaceuticals,
Cheshire, England, and purified as described in section 4.1.2. The anti-KlH
antibody was a reqat lve control antibody oIlhe same isotype as the anti-TNF' a
antibody and was included lor each 01the different stlmutat.ons, including non-
stimulatedcells. The cells werewashed3 limes, 10 minutes each wash, with 0.1%
saponin-PBS.
100 J.l1of phycoerythrin-conjugated goat anl1-racbit 19dituted 10 1:10 inO.1%
saponin-150/0 NHS-PBS were added 10 each well and incubated for ;lOminutes on
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ice. The cells were washed as before.
4.1.30 Detection of Surface CD14 on Monocytes
After washing with 0.1% saponin-PBS, the cells were washed 3 times with
PBS alone on ice. Any residual saponin would keep the cells permeabflized and
the antibodies to determine cell phenotype would enter the cytoplasm. Therefore,
to ensure that the antibodies only bound surlace markers, the saponin was
removed and all further incubations with antibodies were done In saponin-free
buffer.
Anli-CD14 was used diluted 1:10 in 100 1-11of PBS and the cells incubated
on ice for 20 minutes. After washing 3 times with PBS, 100 IJ.I of the secondary
anlibody, FITC conjugated F(ab)2 goat anti-mouse, was added to each wall and
incubated on ice in the dark for 20 minutes. After an additional 3 washes with
PBS, the cells were transtened from the wells to 500 1-11 PBS with 0.02% sodium
azide in 5 mt polystyrene tubes.
Analysis was done on a Becton-Dickinson FACStar"....Flow Cytometer with
an argon laser operating at 50 mW and with filter settings for File (530 nm) and
phycoerythrin (585 nm). 10 000 cells were run per sample and the data were
collected in list mode and later analyzed with Lysys II software. Ernie Stapleton
and Lesl ie Days were the flow cytometer operators.
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4.1.4 Development of Double Staining Flow Cytometry Protocol
At the onset of this study there was no published method for the
simultaneous labelling of cell associated (cytoplasmic) TNF-« and sunace
phenotype marker for a mixed population of PBMC. In 1989 Hotslt et al. described
a method for labelling cytoplasmic TNF-a In purified monocytes for flow cytometry
and lmmu- c'luorescent microscopic study. Simultaneous labelling of TNF-a and
surface anUgen to determine phenotype in a mixed mononuclear population
excludes the need to manipulate the cells to purify a particular subset, which can
affect cell activation. A labe lling protocol, therefore, would have to be one that not
only fixed and permeabilized the cells but also maintained the integrity of the
surface antigens and the forward and side scatler properties of Ihe different
subsets. Maintaining forward and side scatter properties of the cells is important
in helping to gate certain subsets such as monocytes. This section describes the
various methods tested in developing the method of simultaneous labelling of
surface phenotype and cell associated TNF-a.that was described In section 4.1.2.
4.1.4A Stimulation of Cells for TNF-a.Production
In the initial experiments testing the various methods, PBMC were
stimulated with 20 IJ.g1ml l PS for 1, 2, and 3 hours. These times were chosen
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because it was unknown whe n peak cytoplasmIc TNF -a occu rred, and earlier
exper iments (Chapter 3) showe d peak secre ted levers at app roximately 3 hours
afte r stimulati on.
4.1.48 Fixation, Permeabilization and Labelling Methods Tested
The following is a list of methods tested for labelling cytoplas mic TNF-a:;
(1) Schmid.!2L§!. (1991) described a method of flxatlon and permeabiJization
using paraformaldehyde and Tween 20 detergent for staining intrace llular antigen s
and DNA. The stimula ted cells were fixed with 0.5 % paraformaldehyde at 4°C for
1 hour then permeabilized w ith 0.2 % Tween 20 in PBS for 15 minutes. We used
the same polyconal rabbit anti -TNF-a: that was used in the TNF- a ELISA (Chapter
2) diluted in PBS followed by goat antl-rebbn-phycoerythrln to label cytoplasmi c
TNF -Il .
(2) Pollee ~. (1992) descr ibed a sequential para formaldehyde and
methanol f ixationlpermeab ilizalion method for flow cytometri c analysis of
intracellular proteins. We used the same antibodies described above for labell ing
cytoplasmic TNF-« . In addition , some of the cells were labelled with a mouse
monoclonal enti-tubulln (Ced arlane . Hornby, ON) followed by goat anti-mouse-
ph ycoerythr in 10test their permeability .
(3) Absolute methanol at -70 C both fixes and cemeabnees cells at the
same lime (Dr. Atex Szatai, pers. comm unication ). The potyclonat rabbit anti-TNF-
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(t with GAR·PE as described above and a FITC conjugated monoclonal anti-TNF·
(t (R & 0 Systems, Minneapolis) were used to label cytoplasmic TNF·a:. Theanti·
tubulin control was also included.
(4) Late in 1992, de Caestecker eL..aI.. (1992) pUblished a two-color
Immunofluorescence !low cytometrk: assay to( the detection of cytoplasmic IL·1
and TNF·lJ: and surface CD14 expression in whole blood. Instead of using whole
blood, we used LPS stimulated PBMC and fixed with 4 % paraformaldehyde and
penneabilfzed with 1 % saponin as described in the paper. The antibodies
described above were used.
Dr. de Oaestecker suggested (personal communication) trying a number of
different polyclonal antHNF·a: antibodies. Polyclonal rabbit anli-TNF-a:antibodies
from Calbiochem (Palo Alto, CAl, Bic-Design (Maine) and the same antibody Dr.
de Caestecker used, which was a gift from Dr. S. Foster. were tested The
antibody from Dr. Foster gave a weak signal (see Results. section 4.2.1) and this
method was chosen for furthef' work.
To determine the point at which TNF·" reached its peak in the cytoplasm,
PBMC were stimulated with LPS for 30 minutes, 1,2 ,3, 12 and 24 hours and with
ConAJPMA for 1, 12, and 53 t'I u rs. Cells slimulated with ConAIPMA for longer
than 24 hours ruptured either during treatment or during the subsequent washings
and therefore could not be stained. Peak TNF· « in the cytoplasm of LPS
stimulated cells was at 1 hour but the increase in fluorescence above background
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was very low.
To increase the fluorescent signal in weakly fluorescent cells, monensin was
added to the culture medium during stimulation (Jung §Li!. 1993). Monensin
interrupts intracellular transport allowing an accumulation of cylokine in the calf.
One disadvantage of mcnensln was its eventual cytotox icity. Using
propidium iodide (PI) uptake as an indicator of ceUdeath , there was increased
cytotoxIcity after incubation for 16 hours in monensin and this cytotoxicity
increased further with longer incubation periods (see Results, section 4.2.1). This
limited any experiments with monensin to less than 16 hours.
4.1.4C Surfac e Antige n Staining
Surface antigens were stained using the amount of antibody specified by the
manufacturer. However, instead of adding Ihe undiluted antibody as the
instructions indicated, better stain ing was achieved by di luting the antibody 10a
final volume of 100 ~I in PBS.
Itwas important to remove all saponin by washing with PBS before staining
surface antigens. When stained in the presence of saponin, background FITe
fluorescence was high, making it difficult to gate on cells expressing the surface
antigen.
4.1.5 Surface Antigen Staining for Differential Counts of CDl4- , CD4-, CD8·,
100
and C045Ro-po siti ve Cell s
To determine the relative numbers of cell subsets for each individual in the
entire male SllJliy group, PBMC were stained using Slandard protocols and
manufact urers' instructions lor each antibody. Briefly, 100 000 cells/test were
stained with anli-G01 4·FITC, antl-G0 4·FITC, antI-CO& FITC, and anti-C045 RQ-
FITC for 20 minutes in 5 ml polystyrene tubes (Fisher Scientific , Montreal) in the
dark. After 20 minutes the cells were washed with PBS and fixed with 0.5 %
paraformaldehyde.
4.1.6 Stati stical Method s
To lest for correlations between secreted TNF·" levels and the number of
cells in specific PBMC subsets, the data were analyzed by least squares linear
regression using the statistical software InPIot (GraphPad, San Diego). To aRow
for comparisons among the different PBMC subsets, only those subjects with cata
poinls for each of the PBMC subsets 10 be tested were included in the analysis.
Thai is, if a person did not have a data point for all four subsets, CD 14, C04, coa
and CD45RO, then that person was excluded from the analysis .
4.2 Results
4.2.1 Flo w Cytometry Methodology
In the initial experiments cells were only stained lor cytoplasmic TNF·a. Ic
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ens ure that we were not missing a weak signal in the monocyte subset, the cells
were analyzed by selling a gate based on size to display the monocyte subset. A
-gate" is a term used to mean selecting a particular group of cells and only
displaying the data for those cells.
When the cells were stained for cytoplasmic TNF-tt using eithe r of the four
fixation and permeabilization protoco ls, there were no fluorescent signals above
background (Figure 4.1). However, the cells were permeable to the antibodies in
all methods 2, 3 and 4 because they stained positive for cytoplas mic tubulin
(Figure 4.2). Method 1, 0.5 % parafo rmaldehyde + Tween was not tested with anli-
tubulin.
Only by using both the fixation method and polyclonal anti·TNF ·tt that Dr.
de Caestecker had used did we get an increase in fluorescence ove r background.
Incubation of the cells with mooens in during stimulation increased th e fluorescent
sigm.,1 (Figure 4.3). Monensin, however was cytotoxic after incubation for 16 hours
and the cytotoxicity increased with longer incubations (Figure 4.4).
Peak cytoplasmic TNF-« was at 1hour after incubation when 20 j.Lglml LPS
was used to induce production. Figure 4.5 shows that after 1 hour the number of
ce lls staining positive for TNF-a dimin ishes. This experiment was repeated once
with the same results. No cytoplasmic TNF-a data are available for ConAi PMA
stim ulations because for incubations longer than 12 hours the cells ruptured during
the fixation and permeabilization steps.
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FIgure 4.1 : Examples of flow ovtometrv analysis of cytop lasmic staining of
TNF-a In monccvtes using the fixation/permeabilization tech niques that were
uns uccessful. A. 0 .5 % parafor maldehyde + Tween 20. B. 0 .5 %
parafo rmald ehyde + 22.5 % methanol . C. absolute methan ol. and O. 4 %
paraformald ehyde + saponin . The shaded areasrepresent cells not stimula ted
and the open areas represent cells stimula ted w ith 20 pg /ml LPg for 1 hour.
The x-axia shows fluorescence and the v-exie shows the number of cells
A. B.
c. D.
1 2 1"
I ' I' I '
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Figure 4.2 Cytoplasmic tubulln staining in PBMC after fixation and
permeabilization with A. 0.5 % paraformaldehyde + 22 .5% methanol, B. absolute
methanol and C. 4 % paratormatdehyde +saponin. The shaded areas represent
staining with isotype control antibody and the openareas represent cells stained
with antl-tubulb. The x-axleshows fluorescence intensity andthe y-axls show cell
number.
'\/ .,\
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"
B.
c.
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Figure 4.3 : The effect of incubating cells with monensin during TNF·a induction
on the level of TNF-a that can be labelled in the cytoplasmof CD14 monocytes.
The shadedarea represents cells stimulated for 1 hour with LPS in the absence
of monensin and the openarearepresentscells stimulated for 1 hourwithLPS in
the presenceof monensin.
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FIgure4.4 : Cytotoxicity of monensjn 10PBMCafler incubation for 16hours and
longer. Cell death was determined by uptake of propidium iodide. The x-axie
shows fluorescenceand the y-axlsshowscell number. Increasedfluorescence is
indicativeof increasedPI uptake.
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Figure 4.5 : Flow cytometry analysis of kinelic studies to determine when the
maximum number of CD14 monocytes are expressloning cytoplasmic TNF-a after
stimulation with 20 Ilg/ml LPS. A. 30 minutes incubation . B. 1 hour incubation.
C.2 hours lncubetion D. 3 hours incubation. The shaded areas represent non-
stimulated cells and the open areas represent cells stimulated with LPS. The x-axis
shows fluorescence and the y-axls shows cell number.
A. B.
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4.2.2 TNF- a Prod ucing CD14" MonOCy1es
Because the censample Vias PBMC, a gate was set to display only lhe data
forCD14" monocytes . CD14 was detected with antibodies conjugaled to the green
fluorescent molecule FITC, therefore the gate was set 10display the data for the
-green- cells. Cytoplasmic TNF·a was detected with the red fluorescent label
phcoerythrin , therefore, using the computer software Lysis II. tha number of
"green" cells that were also "red" could be counted. Any cells thai stained lor
cytoplasmic TNF-a but not for CD14 would not be included in the analysis.
The re was no consistent relationship between the number of TNF·(l·
producing CD14" monocytes and the amount of secreted TNF-a for 2 subjects
tested. Although the amount 01 secreted TNF·a was relatively consistent for
different experiments, the number of TNF-a producing CD14 ' monncytes was nolo
In one experiment shown in figure 4.6A. 01the C014' monocyte subset, subject
LS has 70% TNF-a producing monocytes while subject SP has 48%. In other
words, for LS, of the cells that stained positive lor CD14 , 70 % also stalred
positive for cytoplasmic TNF·o:. In a second experiment shown in figure 4.6B, bolh
subjects have 10% TNF-a producing monocytes despite levels of secreted TNF-o:
consistent with those from the experiment shown in figure 4.6A. No correlation
could therefore be made between secreted TNF- ~ levers and the number of cells
producing TNF-a in thA samples tested.
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Rgure 4.6 : Flow cy tomet ry analysis of CD14 monocytes stainAd '0( cytoplasmic
TNF-a for LS and SP trom two experiments (A and B). The grey shaded area
represents unstimulated cells, The open area designated by the black line
represents cells stimulated with 20 ~g/ml LPS for 1 hour
A.
V3: 2W49JCee9>.fL2-H"rL2-H"lgh l
R,
B.
LS : Secreted TNF-tl at 3 hours = 3358.5 P9fml
SP : Secreted TNF-a al 3 hours =1173 pg/ml
'JJ I2S11 93AOI6'\fL2- H'F l Z·H"loh l lJ3125 1 1'!lYlOOS'FL2-11',Fl~- lle 'yh\
.,
"
LS : Secreted TNF-u at 3 hours = 3567.5 pg/ml
SP: Secre ted TNF-a at 3 hours = 1500 pgfml
113
4.2.3 Relationship Between PBMC Subsets and Secreted TNF-u
To investigate whether therewas any correlationbetween secreted TNF-u
levels and numbers of cells in specific PBMC subsets, secreted TNF-u levels for
the male subjects in chapter 3 and the per cant of cells in PBMC subsets were
analyzed by least squares linear regression. There was no correlation between
TNF·a secretion based on a 3 hour, 20 J.lg/ml LPS stimulation and numbers of
CD14+monocytes. CD4+T cells, CDa· T cells and CD45RO+T cells. Figures 4.7
-4.9 show the regression lines for the relationship between the number of cells and
TNF-a secretion. The slopes of the regression lines are not statisticallydifferent
Ihan zero (Table 6).
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Figure 4.7 : Best-filting regression line relating levels of TNF·a
secretion to number of C01 4" monocytes in a sample of 10 000
PBMC
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Figure4.8 : Best-fitting regression linerelating levelsof TNF-a secretion to
(A) number ofCD4+ T cellsand (B) number of COB' T cells in a sample of
10 000 PBMC
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FlQ\Jre 4.9 : Best-f itl ing regress ion line relating levels of TNFo" secretion
and number of C045RO ' T cells in a sample of to 000 PBMC
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Table 6: Correlation coefficients (Pearson r) andsignificance levels (P value) for
the regression lines shown in Figures4.7 - 4.9
Cell Type N Pearson r P value
CD14 30 -0.074 0.696
CD45AO 30 0.082 0.665
CD4 30 -0.203 0.28 1
CDS 30 0.310 0.095
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4.3 Discussion
4.3.1 Double Fluorescence Flow Cytometry
With the double-staining flow cytometry protocol developed, we had hoped
to determine which cells in a sample of PBMC, and the proportion of cells of a
particular phenotype that were producing TNF-a after stimulation with 20 I-Lglm l
LPS, 1 nglml LPS and ConN PMA. The response of PBMC from different
individuals to the same kind and dose of TNF-a inducer might answer the question
of whether individual differences in TNF-a secretion arise from individual
differences in the number of cells producinJ TNF-a. Comparing the kinetics of
responses to different inducers in this way might allow us to determine which
particular subset(s) were producing TNF-a under each 01the three experimental
conditions and whether individuals differed In the quanttty of their responses.
Because of the problem with cells disintegrating during fixation and
permeabilizatioo after stimulation with ConNPMA for more than 24 hours, no
experiments could be done with this method to determine which cells were
producing TNF-IX in 53 hour ConNP MA cultures. For this reason no experiments
were done whereby phenotypic markers for CD4+,CDS', and CD45RO' subsets
of T-celis were labelled. In addition, the requirement of monensin during stimulation
to boost the cytoplasmic TNF-IX signal limited the experiments to less than 16
hours. Therefore, the only experiments done were those to determine the number
of CD14+monocytes that were producing TNF-« after LPS stimulation
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Subjects LS and SP were chosen for the dete rmination 01the numbe r of
CD14 monocytes producing TNF·« because PBMC f rom LS secreted 3 - 4 l imes
snore TNF-a than SP when stimulated with 20 Ilglm l LPS for 3 hours. If the level
of TNF·« dete ctable in the supernatants is a function of the number of cell o
producing TNF' a, and CD14' monocyt es are the major producers of TNF ·a , then
LS might be expected to have more CD14' monocytes produc ing TNF·a . The
results, however, were inconsistent because in one experiment both LS and SP
had the same number of monocytes producing TNF-a while in another LS had
22% more monocy tes prod ucing TNF·« . Because of these inconsiste ncies no
concluslor-s cou ld be made and no furthe r experiments were done to examine the
differences when PBMC were stimulated wi th 1 nglml LPS.
The inconsistencie s are probably a result of problems with the method.
Given tha t TN F-a secret ion from both SP and LS is re lative ly stable over time , the
output of TNF 'a on a per cell basis would have to change dramati cally to account
for the diffe rence in the numbe r of cells produci ng TNF -o:. This is unlikely beca use
it would mean Ihat at any given time there is a SPoI leve l of TNF- o:to be secreted
regardless of the number of cells producing it.
Altho ugh this method as it stands was not useful in determining the number
of cells produc ing TNF-o:, il was useful in determining the types of cells producing
TNF-« . In our case it was clear that LPS stim ulated monocytes were producin g
TNF-« .
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The reason or reasons why the cells disintegrated alter stimulation with
ConAfPMA are unknown. The use of gentler fixative or a genUer permeabilization
technique may reduce the problem but de Caestecker~. (1'992) did point out
that they had tested a number of different fixatives andpermeabilizationtechniques
and the 4 % paraformaldehyde followed by 1 % saponin was the best method for
detection of intracellular TNF-« . Their stimulations. however. were only with
LPS.
The problem of monensln limiting the use of the double-labelling protocol
to 16 hours and less could be overcome if manensin could be added to Ihe
cultures in the last several hours of incubation instead at the beginning. For
example, to determine which cells were producing TNF-« at 24 hours after
stimulation with ConAlPMA, one may be able to add monensin to the cultures at
22 hours so that any TNF-« being produced would accumulate in the catls during
the last two hours 01 st imulation.
4.3.2 Numbers of Cells and Secreted TNF-lX
The lack of correlation between TNF-« and the number of cells of the
PBMC subsets would mean that the amount of TNF-« secreted by PBMC
stimulated with LP5 is not dependant on the number of cells of any given
phenotype teared. This suggests that the level of TNF-« detectable in the PBMC
supernatants is a function of the rate of transcription/secretion and/or removalfrom
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the supernatants, not the number of cells. Adding to this argument and assuming
CD14 monocvtee produce most of the TNF-u etter LPS stimulation, is the finding
that LS consistently had about half the number of CD14 monocytes as SP yet
secreted more TNF-u . The work by Molvig ~. (1988) suggests the same
phenomenon because they showed interindividual differences when fixed Quantities
01monocytes were used. If the level of TNF-a detected was due to individual
differences in the proportion of TNF-u-secreting cells then, in homogeneous
cultures with the same numbers of cells, you wo uld expect all individuals to
manifest approximately the same amount of TNF-a .
Inherent differences in rates of TNF-« secretion per cell may account for
interindividua l differences with LPS stimulations because in these cultures TNF ·«
peaks early and is produced primarily by monocytes . 11 may not be the only reason
for the different response to ConA/PMA. We know that PMA induces 'l-cells to
secrete TNF-a and Can A has a proliferative effect on 't -cells . The amount of TNF-
a secreted might therefore be partially dependant on the amount of T-cell
proliferation. Thus "high"r low" differences detected in the supernatants f rom
ConAiPMA culture could be effected by both the diffe rence in rate of transcription
by one or aflpapulal ions of cells activated by PMA and, in long-term culture, by
Increasing numbers of T-cells. If them are constitutive differences in rate of TNF-a
secretion per cell then, all things being equal, the Quanmat ively greater difference
should be in the ConAJPMAculture bUIconsistent, le. in the same direction, as th;
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LP$ cultures. This was not the case in our experiments , suggestingthat the TNF-
(l in the eupe.natants after LPg and ConNPMA stimulations result from a different
series of events.
The lack of any correlation with lymphocyte numb ers and TNF-« induced
by LPg for 3 hours is not surprising given that LPg is not known to stimulate
lymphocytes to produce TNF-a . However, lymphocytes express TNFreceptors and
could possibly influence TNF-« in several ways . First. they can contribute to the
removal of TNF-a from the cultures by binding TNF-(l and promoting its
degradation. Secondly, TNF-a can act as an autocme hormone and stimulate its
own production . 't-eens might. therefore secrete some TNF-a after stimulation with
TNF-a SEcretedby the monccytes.
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Chapter 5
General Conclusion s and Futu re Direction
A number of conclusions canbe dr'::~' :n from the resultsof thesestudies.
(1) There is ccnslderabte interindlvldual va riation in LPS induced TNF-a
secretion by PBMC from healthy. young males whic" appea rs, from the limited
data, In be moderately stable . Thus, three studies, this one plus those by Molvig
§l..& (1988) and Jacob~ (1990), using different methods 10 induce TNF-«
secretion haveshown stable, interindividualvariation in levels ofTNF-" secretion.
In contrast, PBMC from pre-menopau sal females show wide fluctuation in levels
of lpg-induced TNF-a secretion when tested over a four week period.
(2) The assoclauc« between If)WTNF-« secretion and HLA-DA2 reported
by Molvig~ (1988) and Jacob gUh (1990) was not confIrmed in this study.
Interestingly, our data has demonstrated an association between HLA-DR3 and
lowTNF·a secretion. The associationwith OR3 was not highly significant and the
numberof HLA·DA3 individuals was relativelysmall. However,the levels of TNF-a
secretion for the DR3+individuals are within a much narrower range with a lower
standarddeviation and less variability that the TNF'a levels from DA2 and DR4
individual...
The confounding factor in thesetypes of studies is the use or individuals
heterozygousfor HLA·DR alleles. Manyof the individualsin our studyand possibly
in Jacob's. althoughno mention is given10thenumberof homozygousindividuals,
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were heterozygous at the DR locus. Therefore. the need exists for a properly
controlled study. The appropriate study here is a family study. If high and low TNF·
a secretion is inherited and associates with HLA·DR, then one would expect that
this could be clemonstrated by family studies of HLA-DR alleles and TNF·u
secretion. The ideal families would contain al least one homozygous DR and
homozygous high/low TNF-a secreter. A sample of individuals homozygous at the
DR locus would also be informative . In the nnefysls of the secreted TNF-It levels
one would not have to consider the possible contribution of the putative high or low
TNF·a expressing gene associated with the different HlA allele on the other
chromosome.
In view of the kinetics results, the possibility exists that cells stimulated
under different conditions show different associations. This should be tested in a
population study in which all individuals are typed for HLA antigens and TNF' a
secretion induced by the three stimulation protocols descr ibed in chapter 3, It
would also be informative to compare the kinetics of TNF-a secretion from PBMC
using different stimulation protocols for DR3 +and DA3' individuals and DA2 ' and
DR2' individuals.
(3) The kinetics of T(l.JF-a secretion by PBMC is similar for cells of different
Individuals under the same stimulation conditions. ThUS, results from a single time-
sample for several individuals are likely to be a fairly accurate reflection of
individual differences in the popu lation.
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(4) The kinetics of TNF-" secretion by PBMC stimulated with LPS are
dramatically different lrom the kinetics of TNF-·:x secretion obtained with
ConAiPMA stimulation. There are a number of mechanisms which might contribute
to Ihese differences, such as different signalling pathways of LPS and PMA, LPS-
receptor downregulation by LPS, TNF· o: receptor downregul ation by PMA and T
cell proliferation by Con A.
This observation was important because, for the indiv iduals tested, the rank
order based on levels of TNF-« detected in the supernatants was dependent on
the type of TNF-« inducer and the concentration. One individual ldentltled as a
"high" TNF-« secretor under one stimulation protocol could be a "low" secretor in
another. This has implications for studies on the genetics of TNF-« expression
because it would imply that the differences in Ihe amounts of TNF-et secreted are
not entirely determined by the TNF-« gene, or polymorph isms at the TNF locus.
This may also explain the conflicting data of Jacob eu.J. (1990), Molvig eLm.
(19S8)and thaI presented in this study with respect to assoc iations between TNF-
0: secretion and other genes in the MHC.
The possibility 01LPS-receptor downregulation by LPS, PMA downregulation
of TNF-(l receptors and T cell proliferation as reasons for the diffe rences in the
kinetics of TNF-a secretion can all be investigated by flow cytometry. In kinetic
experiments similar to those described in chapter 3, cells could also be removed
at each time supernatants are harvested. The LPg receptor CD14 and TNF-"
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receptors on the cell surfaces could be labelled with fluorescen t antibodies and
analyzed by flow cytometry. The strength of the fluorescent signal would be
proportional to the number of receptors expressed on the cell surface. T cell
proliferat ion could be determined by doing differential counts as described in
chapter 4.
(5) The level of TNF-a detected in the supernatants of PBMC stimulated
with LPg for 3 hours seems to be unrelated to the number of CD14' calls in the
sample tested. In our experiments however, the number of CD14 cells in the
PBMC sample was determined the day before the cells were stimulated . A better
way to determine if the number 01CD14 cells in a PBMC sample is related to the
amount of TNF-a detected in t!KJ supernatants is to count the number of CD14
cells in the sample by flow cytometry at the time the supernatants are harvested.
Altematively, a bailer method might be to measure the transcription rates of the
cells from different individuals with different stimulation condlttons using nuclear
run-on assays. The advan tage of nuclear run-on assays in measuring transcription
rates is that they measure nascent mANA, unlike Northern Blot analysis where
cytoplasmic mRNA is also measured.
Together, these experiments could tell us if there are differences in
proliferation rates between individuals when different stimulants are used, ir there
are different rates of TNF-a receptor up- or down-regu lation, and 1ITNF-a mANA
transcription rates differ between individuals when PBMC are stimulated by
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differenl TNF-o: inducers for different lime periods.
The problem of monensin limiting the use of the double-labelling protocol
to 16 hours and less could be overcome If monensin could be added to the
cultures in the last several hours of incubation instead at the beginning. For
example, 10 determine which cells were producing TNF-a at 24 hours after
stimulation with ConAiPMA. one may be able to add monensin to the cultures at
22 hours so that any TNF-a being produced would accumulate in the cells during
the last two hours of slimulation.
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Appendix A
SecretedTNF-a and HLATypes for the Male Study Panel
- - - - - - - --- - - - - - - - - - - - - - - -
Subject TNF-" HLA·A HLA·B HLA·DR
pglml
- - - - - - - - -- - - - - - - - - - ------
780 879.5 1 8,12
050 1415 3,29 12,35 2,4
270 1561 11 15,40 2,4
370 868.5 1 57,63 1,7
650 802.7
720 1357 2,11 44 5,6
730 741.1 2 21 7
190 906.2 1,29 8,44 7
240 696.4 2,11 51,57 6,7
810 1070.5 30,32 44,13 3,7
360 1484.5 3,29 7,44 6
560 1056.7 26 8,35 3,11
330 1213.5 1,3 7,8 15,6
550 818.8 1,31 8,13 1,3
390 2587.5 24,25 8,44 11,6
420 1794.5 11,31 8,40 1,6
280 963.9 1,2 7,27 4,6
290 750.5 1,3 6,27 3,8
300 788 2 14,15 11,7
320 1368.5 9,10 51,27 5,8
310 2345.5 9 8,40 4,5
340 1585.5 1 17,40 2,8
350 1088.7 1,30 38,40 4,6
360 548.9 1,2
410 1026.6 31 8,14 3
400 3215.5 9,32 17,44 6,7
430 1183.5 3,26 7,44 2,4
440 2475.5 9 17,40 2
450 904.45 2,29 45 4,7
460 1189 1,2 17,18 2,5
470 1370.5 3,24 7 2
480 1713 1,28 8,70 4,9
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490 813.2 11,30 51,44
500 625.55 3.32 40,62
510 731.6 1 44 1,7
520 1557.5 i .30 38,35
530 739 .05 11 51,63
540 1005.4 2 7.27 1,2
600 844.35 1,24 35 5,10
590 844.4 1,3 8,44 3,5
580 1099 1,3 51,57 4,7
570 1185 3,24 7,62
620 725.05 1,24 7,8 1,3
640 2557.5 2,26 62.39 2,8
630 1393.5 2,26 51,44 4,6
610 1983 3 7,35 1
660 2068.5 1 7,57
670 1541.5 2 14.35 2
680 1611 2,3 7,50 5,7
690 1312 3,11 7,18 2,5
700 802.3 31,32 18,40 3,4
710 3900 1,2 8,44
770 689.2 3 8,67
820 898.8
830 1295 3,6
840 1233.S
850 428 .25 2,3 18,44
860 157.7 2 48,57 6,7
870 1309
960 1326.5 3 7,35
970 494 .05 2,3 7
980 1051.5
990 617.25 1,2 8.44
1000 513.35
1010 516
1020 1033.4 24,28 7
1030 1430.5 2,24 44
'040 930.4 1,11
1050 888.5 1 62,8 3,6
1060 1014.5 1,2 7,8 2,6
1070 650.5 1 35 2,6
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AppendixB
Secreted TNF-a and Differential PBMC Subset Counts for the Male StudyPanel
---- - - - - - _. _ - - - - - - - - - - -
Subject TNF·a CD14 CD4 CD8 CD45RO '
pglml
780 878.5 13.4 55.48 9.88 23 .95
050 1415 4.25 38.8 21.09
270 1581 3 23.64 18.48
170 2508 7.33 19.61 26.99
370 868.5 45.98 20.61 23 .31
650 802.7
720 1357 21.29 19.77 7.08 22.79
730 741.1 22.87 40.9 15.09 14.64
190 906.2 3.64
240 696.4 1.67 14.84 6.75
810 1070.5 40.43 29.19
380 1484.5 20.99 30.73 25.56
560 1056.7 5.34 40.09 33.11 17.1
330 1213.!i 4.5 37.03 10.85 18.89
550 818.8 9.62 47.72 12.17 23.04
390 2587.5 40.36 24.12 23.06
420 1794.5 11.2 42.1 19.04 31.74
280 963.9 1.9 35.57 18.85
290 750 .5 5.04 54.74 22 .28
300 788 3.17 35.37 20 .48
320 1368 .5 10.62 45.46 17.1
310 2345 .5 7.83 37.36 23.7 1
340 1585.5 33.19 22.08 19.63
350 1088.7 7.55 28.55 21.13 25.07
360 548.9 5.3 27.29 16.01 18.16
410 1026.6 7.7 38.91 25. 17 37.32
400 3215.5 5.7 1 32 .74 33.04 27.22
430 1183.5 6.05 33 .51 8.82 14.16
440 2475.5 5.55 32.53 32.49 24.68
450 904.45 2.91 42.84 24.77 20 .31
460 1189 9.56 33.1 19.52 18.82
470 1370.5 18.41 40 .65 19.46 17.61
480 1713 15.25 38.29 23.18 16.68
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490 813.2 15.31 31.54 20.47 30 .85
500 625.55 9.93 33.25 13.58 13.08
510 731.6 7.13 30.66 33 .28 23.79
520 1557.5 11.19 30.04 18.4 27.29
530 739.05 2.7 1 43.6 26 .52 16.78
540 1005.4 4.74 50.73 30.21 27.55
600 84 4.35 34 .03 14.47 15.36
590 844 .4 42.16 23.02 15.57
580 1099 14.71 27.12 18.47
570 1185 51.15 16.28 24 .12
620 725.05 11.67 43.58 17.32 18.59
640 2557 .5 11.39 35.24 15.94 11.89
630 1393.5 31.42 19.74 25 .71
610 1983 44.88 22.89 13.39
660 2068.5 12.11 42.52 23.66 25.4 1
570 1541.5 4.53 49.85 17.3 23 .44
680 1611 1.18 37.62 19.06 26 .27
690 1312 2.37 53.92 21.44 31.48
700 802.3 2.B7 44.95 15.3 26 .36
710 3900 18.21 5.7 17.6
no 689.2 18 .31 53.51 15.6 22 .75
820 898.8 8.01 43.68 16.59
830 1295 6.06 59 .24 25.84
840 1233.5 10.31 38.56 32 .89
850 428 .25 3.39 36.17 47 .5
860 157.7 3.31 57.69 22 .75
870 1309 12.72 48.65 34.15
960 1326.5 7.35
970 494 .05 16.76
980 1051.5 14.66
990 617.25 10.16
1000 513.35 9.08
1010 516 5.25
1020 1033.4 13 .16
1030 1430.5 11.23
~ 040 930.4 9.91
1050 888 .5 13.25
1060 1014.5 7.64
1070 650 .5
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